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Parkinson’s disease (PD) is associated with reduced dopaminergic (DA) input to the 
dorsal striatum (DS). This study investigated the role of DA in modulating automatic, stimulus-
driven reactions by assessing contextual control of stimulus-locked responses (SLRs) in 10 PD 
patients off and on DA medication. The SLR is the rapid recruitment of limb muscles that drives 
the arm towards suddenly appearing stimuli. Participants reached away from (anti-reach) or 
towards (pro-reach) a target on a screen, depending on instruction appearing 500 or 1000 ms 
before target appearance. Modulation of SLRs was assessed by comparing SLR magnitude on 
anti- and pro-reach trials using surface electrodes. We predicted patients would exhibit less 
modulation of the SLR while off medication, especially with only 500 ms of instruction. Patients 
modulated the SLR less with 500ms of instruction, but there was no effect of medication state, 
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Summary for Lay Audience 
 
Parkinson’s disease (PD) is a movement disorder best known for its motor symptoms 
such as bradykinesia (slowness of movement), tremor, rigidity, and freezing of gait. 
Paradoxically, PD impairs the ability to initiate voluntary movement, but leaves automatic 
movements triggered by external targets (e.g. quickly reaching towards a moving object) intact 
and uninhibited. PD is associated with significant death of the cells responsible for producing 
dopamine (DA) molecules in the brain pathway to the dorsal striatum (DS), the input region to 
the basal ganglia (BG). The BG are a set of nuclei in the brain that modulate movement by 
regulating opposing activating and inhibitory signals to various brain structures involved in 
movement. This study aimed to investigate the ability of PD patients to contextually control fast 
visuomotor responses by assessing their modulation of the stimulus-locked response (SLR). The 
SLR is the earliest wave of arm muscle activity in response to a suddenly appearing target, that 
always drives the arm towards the target. The contextual control of the SLR was measured by 
comparing the magnitude of the response when the participants were instructed to reach away 
from the target (anti-reach) to when they were instructed to reach towards it (pro-reach). The 
colour of a square on the screen indicated whether it was an anti- or pro-reach trial either 500 ms 
or 1000 ms before the target appeared. Participants completed one session off their DA 
medication, and one session on their medication. We found that the ability to modulate the SLR 
was improved when participants had a longer instructional cue. However, even when the task 
was most challenging with only 500 ms to process the instructional cue, there was no difference 
in the contextual control of the SLR off and on medication. Overall, this suggests that the ability 
to generate and control the SLR is unaffected by the DA deficit in PD, however data from a 
healthy control group is needed to confirm this conclusion. 
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1 Introduction  
 
1.1 Parkinson’s disease 
 
1.1.1 Aetiology and Pathology  
 
Parkinson’s disease (PD) is a prevalent movement disorder, widely recognized by slowed 
voluntary movement, tremor, rigidity, and freezing of gait. The incidence of PD increases 
sharply over the age of 65 years old and is most often the result of a combination of genetic and 
environmental factors (Lill & Klein, 2017).  PD is classified as a neurodegenerative disease due 
to the progressive loss of dopaminergic neurons in midbrain structures. At the time of symptom 
onset, more than 50% of the dopaminergic neurons in the substantia nigra pars compacta (SNc) 
have degenerated, resulting in dopamine (DA) depletion in the downstream basal ganglia (BG; 
Cheng et al., 2010). Pathological dysfunction of the BG circuitry results in the manifestation of 
hallmark motor, cognitive, and emotional deficits.   
The BG are a network of subcortical nuclei which receive afferent projections from the 
cortex, thalamus, SNc, and ventral tegmental area (VTA) via the dorsal striatum (DS; Squire et 
al., 2012). The primary output regions of the BG are the substantia nigra pars reticulata (SNr) 
and the internal segment of the globus pallidus (GPi), which send inhibitory gamma-
aminobutyric acid (GABA)ergic projections to various downstream targets involved in 
movement and cognition. The BG circuitry relies on dopaminergic input from the nigrostriatal 
pathway to precisely regulate activity of two opposing pathways involved in modulating this 
inhibitory output: the direct and indirect pathways (Obeso et al., 2008). Dopaminergic input from 
the nigrostriatal pathway is taken up by D1 and D2 receptors on medium spiny neurons (MSN) 
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in the DS. Importantly, DA has excitatory post-synaptic effects on D1 receptors, and inhibitory 
effects on D2 receptors (Obeso et al., 2008; Fuxe et al., 2006). MSNs constituting the origin of 
the direct pathway predominantly express D1 receptors and are therefore activated upon 
dopaminergic input. In contrast, MSNs of the indirect pathway predominantly express D2 
receptors and are hyperpolarized by DA. This antagonistic mechanism is critical for behavioural 
modulation, because the direct and indirect pathways have opposing influence on BG output to 
various structures, including the motor nuclei of the superior colliculi and thalamus, which 
ultimately modulates the cortex (Figure 1; DeLong & Wichmann, 2015; Terao et al., 2017). The 
direct pathway is composed of GABAergic connections from the DS to the GPi and SNr. 
Because the efferent projections from the SNr and GPi to the SC and thalamus are inhibitory, the 
direct pathway promotes action initiation by releasing the motor neurons in the SC, and the 
excitatory signals to the cortex via the thalamus, from tonic inhibition. The indirect pathway has 
the opposite effect. Inhibitory projections from the DS to the external segment of the globus 
pallidus (GPe) supress the inhibitory projections from the GPe to the subthalamic nucleus (STN), 
which in turn increases glutaminergic activation of the SNr and GPi, and therefore increases net 
inhibitory output to target structures. In PD, dopaminergic cell death in the nigrostriatal pathway 
disrupts the balance between the direct and indirect circuits due to a decrease in activation of the 
direct pathway, and a lack of inhibition of the indirect pathway. Behaviourally, the effect of the 
denervated striatum translates to a variety of cognitive, affective, and motor impairments. 
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1.1.2 Motor Symptoms of PD 
Motor symptoms of PD include bradykinesia (i.e., slowness of movement), 
akinesia/hypokinesia (i.e., reduced number and amplitude of movements), tremor, rigidity, and 
freezing of gait (Jankovic, 2008, Moustafa et al., 2016). Bradykinesia and akinesia are among the 
first symptoms to appear in PD and are well-evidenced in studies of reaction times. Compared to 
healthy controls, PD patients have significantly longer reaction times, especially in the absence 
Figure 1 Schematic of the basal ganglia circuitry. The direct pathway is downregulated in Parkinson's disease 
and the indirect pathway is upregulated. 
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of an external stimulus to elicit or guide the movement (i.e., internally-guided movements) 
(Berardelli et al., 2001). Patients exhibit slower movements, with reduced velocity and 
acceleration, as well as decreased magnitude of motions (e.g., smaller reaches, abnormally small 
hand writing). Akinesia/hypokinesia is demonstrated by difficulty initiating volitional 
movements, as well as a loss or reduction of spontaneous movements, such as arm swinging 
while walking and facial expressions (Mardsen, 1989). Electromyography (EMG) studies have 
identified abnormalities in the muscle activity of PD patients performing volitional actions. 
Specifically, movement-related EMG activity is reduced relative to that of healthy controls, and 
rises more slowly after onset, which results in the muscle taking longer to generate sufficient 
force to initiate movement (Berardelli et al, 2001). An EMG study investigating recruitment of 
the biceps muscles reported that simple elbow flexions were significantly slower than those of 
controls, and there was no increase in co-contraction of agonist muscles, suggesting the deficit 
was caused by an impairment in the ability to recruit the participating agonist muscle efficiently 
(Beradelli et al., 1986). Hallett and Khoshbin (1980) demonstrated that in comparison to the 
typical triphasic EMG bursts preceding fast movements, the first burst of EMG activity is 
significantly smaller in PD patients, which is accompanied by additional cycles of bursts to 
compensate. Reduced muscle recruitment is not the result of weakness, as PD patients are able to 
increase the strength of muscle activity with more demanding tasks, but the problem lies in the 
ability to appropriately scale their muscle recruitment to task demands compared to controls 
(Berardelli et al., 1986).  
  Tremor is a very common symptom of PD, and at least 70% of patients present a tremor 
during some point of disease progression (Helmich et al., 2012). In PD, tremor generally occurs 
only at rest or with greater frequency and amplitude at rest compared to during the maintenance 
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of a posture or performance of an action (Moustafa et al., 2016).  Rigidity refers to the subjective 
feeling of stiffness, as well as an increased resistance to passively or actively moving muscles, 
limbs, the neck, or trunk. Rigidity also leads to common (e.g., stooped posture), as well as 
uncommon (e.g., pisa syndrome in which patients lean) postural abnormalities.  Nearly 
universally, PD patients present with a stooped posture caused by neck flexion, rounding of the 
shoulders, as well as flexion at the hips, which causes patients to lean forward.  Less commonly, 
patients might lean to one side quite noticeably, referred to as the Pisa Syndrome (Jankovic, 
2008). Freezing of gait and postural instability significantly impact the independence and quality 
of life of patients. Freezing of gait refers to the feeling that the feet are stuck to the floor.  
Patients with freezing of gait have difficulty and hesitancy in initiating walking, as well as abrupt 
cessation of stepping during ambulation.  Patients with freezing of gait have greater variability in 
stepping, frequently producing tiny, hesitant steps as well as complete cessation. It tends to 
manifest more often in crowded places and narrow environments.  Freezing of gait significantly 
increases the patient’s risk of falling. 
 
1.1.3 Dopamine Therapies for PD 
 
Although there is no cure or neuroprotective therapies available for PD, symptoms are 
commonly and effectively treated with exogenous supplementation of DA.  L-3,4-
dihydroxyphenylalanine (levodopa), the metabolic precursor to DA, is the standard 
pharmacological treatment of the motor symptoms of PD (Davie, 2008; Fahn & Poewe, 2015). It 
is administered orally in conjunction with carbidopa, a peripheral decarboxylase inhibitor, to 
prevent the premature conversion of levodopa to DA by aromatic L-amino acid decarboxylase 
before levodopa crosses the blood-brain barrier (Muller, 2013). This greatly improves the 
bioavailability of orally administered levodopa in the brain, as DA itself cannot pass the blood 
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brain barrier, and therefore cannot reach the SNc if converted in the peripheral nervous system 
(LeWitt, 2015). Once in the SNc, levodopa is metabolized, which effectively replenishes DA to a 
functional level, thereby correcting the imbalance between activation of the direct and indirect 
BG pathways (Hood et al., 2007). Levodopa has a half-life of 60-90 minutes and is typically 
taken multiple times per day to maintain sufficient DA supply to the DS, the brain region that is 
first and most significantly DA depleted in PD (Salat & Tolosa). Alternatively, motor symptoms 
are treated with oral administration of DA agonists, which act by mimicking DA and stimulating 
post-synaptic DA receptors in the brain, and similarly restore function to the DS, which is 
reciprocally connected to most of the cerebral cortex.    
 
1.2 Fast Visuomotor Responses  
 
 1.2.1 Fast Visuomotor Responses in PD   
 
A seemingly paradoxical, but increasingly evident feature of Parkinson’s disease (PD) is 
the preservation of fast visuomotor responses alongside the significant deficits in volitional 
movement. This is apparent in the results of Merritt et al. (2017), which demonstrate the ability 
of PD patients to produce extremely rapid alterations to reach trajectories mid-movement. The 
study employed a pointing paradigm in which participants were instructed to point to a visual 
target, which unexpectedly jumped to a new location during the saccadic eye movement towards 
the target on some trials. PD patients were able to make appropriate online adjustments to the 
trajectory of their reach when the target was suddenly displaced, regardless of whether the target 
jump was consciously perceived. Additionally, the modification of the reach trajectory was 
performed at the same point in the movement by PD patients and healthy controls. These results 
suggest that the ability to rapidly transform visual information into short-latency (~100 
ms) motor commands is unaffected by PD.   
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The results of Merritt et al. (2017) contradict the previously reported findings of 
Desmurget and colleagues (2004) who tested online reach corrections in a traditional double-step 
paradigm, in which participants were instructed to reach towards a target that was unexpectedly 
displaced to a new location upon hand movement onset. They found PD patients were unable to 
modify their ongoing reach when the target was displaced compared to healthy controls, as 
patients made more errors on the task, and took longer to adjust their reach in response to target 
displacement. The discrepancies in the results of these two studies can likely be explained by the 
failure of Desmurget et al. (2004) to account for the confounding effect of bradykinesia on the 
length of the preparatory period preceding the start of the reach. Because target displacement 
was triggered by hand movement onset, participants with longer reach reaction times had an 
extended period of time to program their reach trajectory towards the target’s original location. 
The length of time between initial target onset and target displacement has been shown to 
affect participants’ ability to modify the reach in young healthy populations (Komilis et al., 
1993; Liu & Todorov, 2007; Sarlegna & Mutha, 2015). Consequently, the paradigm employed 
by Desmurget et al. (2004) inherently favored participants with shorter reaction times and 
rendered PD patients at a significant disadvantage.  Conversely, the paradigm used by Merritt et 
al. (2017) successfully controlled for the effect of bradykinetic reaction times in the PD group by 
having target displacement triggered by saccadic eye movement, rather than hand movement, 
which did not differ between PD and control participants.   
The finding that fast, automatic adjustments to reach trajectory are generated with the 
same speed and precision in PD patients and healthy controls is congruent with the hypothesized 
role of the dorsal striatum (DS) in the modulation of automatic movements. Functional magnetic 
resonance imaging (fMRI) studies have linked DS activity to the suppression of automatic 
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responses in favour of the task-appropriate response (Cools, 2006; Ali et al., 2010; Liu et al., 
2010; Zandbelt et al., 2013). Accordingly, DS dysfunction in PD is strongly associated with 
hyper-automaticity and difficulty suppressing reactions towards salient stimuli (Jahanshahi et al.,
2015). The tendency for PD patients to perform the more automatic response over responses 
requiring greater control has been thoroughly documented in studies of cognition (Brown & 
Marsden, 1988; Henik et al., 1993; Dujardin et al., 1999), and is more recently becoming 
apparent in studies of motor control. Specifically, PD patients make more errors on tests of 
reaction inhibition, such as the stop-signal reaction time test and go-no-go test (Obeso et al., 
2008; Gauggel et al., 2004; Beste et al., 2010). 
Failed inhibition of visuomotor activation in PD is demonstrated in the findings of 
Praamstra et al. (2001), who studied the effect of spatial stimulus-response compatibility (i.e., 
the Simon Effect; Simon, 1990) on reaction times of PD patients and healthy controls. The 
Simon Effect describes the tendency of participants to respond more quickly when the direction 
or location of the response corresponds to the location of the appearing visual stimulus. Shorter 
reaction times on trials in which the appropriate response and the stimulus are on the same side 
of the display are thought to be the result of a more automatic, stimulus-driven motor pathway, 
whereas responses on the opposite side to the stimulus are thought to be mediated by a more 
cognitively controlled pathway. Actions mediated by the volitional motor pathway are 
susceptible to interference from stimulus-driven responses, yielding longer reaction times 
(Kornblum et al., 1990). Praamstra et al. (2001) employed a paradigm in which a cue to respond 
with either the left or right hand suddenly appeared in a box on either the left or right side of the 
screen. Responses were made by squeezing the left or right hand on manipulanda according to 
the instructional cue. The effect of stimulus-response compatibility, measured as the difference 
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between reaction times on stimulus-response compatible vs incompatible trials, was greater for 
patients with PD than healthy controls. Further, patients made more directional errors than 
controls on stimulus-response incompatible trials. Therefore, inhibition of the tendency to 
respond on the side of the visual stimulus was comparatively impaired in the PD group. 
Additionally, PD patients consistently differ from healthy controls on oculomotor tasks. 
When patients are instructed to look towards a stimulus target when it appears (pro-saccade), 
they make more short-latency (90-140ms) express saccades than age-matched controls.  
However, in the absence of a visual stimulus, the latencies of memory-guided saccades are either 
delayed or undistinguishable from controls (Briand et al., 1999; Chan et al., 2005; Terao et al., 
2011; Lu et al., 2019). PD patients make more directional errors (i.e., saccades towards the 
stimulus) and have longer saccadic reaction times on the anti-saccade task, in which they are 
instructed to perform a saccade away from the stimulus or in the opposite direction from which it 
appeared (Briand et al., 1999; Chan et al., 2005; Terao et al., 2011; Terao et al., 2013; Lu et al., 
2019).  Moreover, when participants are instructed to keep their gaze directed at a fixation point 
and refrain from making a saccade towards a visual stimulus when it appears, they have more 
difficulty suppressing the automatic saccade towards the stimulus and make significantly more 
errors than healthy controls (Hood et al., 2007). These tasks assess the ability to select between 
competing automated stimulus-driven, and voluntary goal-driven responses. Together, these 
findings suggest detrimental effects of DS dysfunction on the modulation of automatic 
responses, resulting in intact and uninhibited fast visuomotor responses, but impaired controlled 
visuomotor actions.   
There are a variety of studies in the current literature highlighting a deficit in PD patients 
when switching tasks from one to another (Lees & Smith 1983; Gauntlett-Gilbert et al., 1999; 
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Dimitrov et al., 1999; Cools et al., 2001). Cameron et al. (2010) investigated whether the relative 
automaticity of the two tasks influences this behavioural deficit and found that PD patients have 
trouble switching tasks to a less automatic action but have an advantage over healthy controls 
when switching to a more automatic action. Participants were instructed to focus their attention 
on a fixation point, which was red or green to indicate an anti-saccade or pro-saccade trial 
respectively. A target then appeared to the left or right of the fixation point, and participants 
generated either an anti- or pro-saccade accordingly. On some trials, the colour of the fixation 
point suddenly changed either just before, concurrent with, or just after target appearance, 
making the participant change their response from a pro- to anti-saccade or from an anti- to pro-
saccade. On pro-to-anti trials PD patients made significantly more directional errors than healthy 
controls, whereas on anti-to-pro saccade trials PD patients made fewer directional errors than 
controls. Moreover, PD patients made fewer directional errors on anti-to-pro trials than on non-
switch anti-saccade trials, unlike controls who always performed better in the non-switch 
condition. These results demonstrate the response bias towards the more habitual behaviour, and 
the deficit in overriding automatic, but not volitional, oculomotor responses in patients with PD.  
 
1.2.2 The Stimulus-Locked Response (SLR) 
 
An empirical measure of output from the fast visuomotor pathway is the stimulus-locked 
response (SLR). The SLR is the first burst of muscle activity that appears on neck and limb 
muscles following the sudden appearance of a visual stimulus. Specifically, the appearance of 
the SLR is well-documented in non-human primates and humans on dorsal neck muscles 
involved in turning the head, and the pectoralis major and deltoid posterior muscles involved 
in whole arm reaching (Pruszynski et al., 2010; Goonetilleke et al., 2015).  This response is 
detected as an excitatory or inhibitory change in EMG activity on agonist and antagonist muscles 
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respectively, to orient the head or limbs towards the stimulus (Corneil et al., 2004; Pruszynski et 
al., 2010; Chapman & Corneil, 2011; Gu et al., 2016). In reaching tasks in which participants are 
instructed to reach towards a visual target as soon as it emerges, the SLR is apparent in EMG 
activity within < 100 ms (Pruszynski et al., 2010; Gu et al., 2018). 
 
1.2.3 SLR Magnitude, but not Latency or Directionality, is Influenced by Movement Goal  
 
The defining feature of the SLR is its extremely short latency relative to stimulus 
appearance (< 100 ms). On a trial-to-trial basis, the onset of the SLR is more time-locked to 
stimulus onset, than to movement onset. This response is clearly distinct from the subsequent 
muscle recruitment associated with voluntary reaching, as the latency of the SLR does not 
change with variance in reaction time (Pruszynski at al., 2010), and is unaffected by task 
complexity (Gu et al., 2018). The time required to initiate a volitional reaching action in response 
to a visual stimulus (~200 ms) is much longer than the time required for visual information to 
reach the cortex and the resulting motor command to reach the arm muscles via the corticospinal 
tract, leaving time for cognitive processing and integration of pre-planned, top-down instruction 
to modulate the action (Welford, 1980). Reaction times of voluntary movements are 
consequently longer on more complex tasks due to increased cognitive processing time. In 
contrast, Gu et al. (2018) demonstrated that increased complexity of reaching tasks, for example 
by requiring subjects to move around or through objects to reach a target, has no influence 
on SLR latency, despite increases in reach reaction times. Instead, such increases in task 
complexity lead to reduced SLR magnitudes. Analogously, the latency and accuracy of online 
reach corrections are unaffected by increased task complexity or simultaneous performance on a 
cognitively demanding task (Liu et al., 2008; McIntosh et al., 2010). Therefore, a key 
distinguishable feature between automatic visuomotor responses and volitional muscle 
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recruitment is that the cognitive load required to prepare the planned motor goal has no influence 
on the timing of the pathway linking visual information to the earliest phase of muscle 
recruitment. 
Functionally, the SLR facilitates rapid coordination of stimulus-targeted responses to our 
complex and ever-changing environment. The strong negative correlation between SLR 
magnitude on arm muscles and reaction times of reaches towards the stimulus implies a benefit 
of automated muscle recruitment when the reaching goal corresponds to the location of the 
stimulus (Pruszynski et al., 2010). However, with such short latencies, there is little time 
between stimulus emergence and SLR onset for cognitive control or inhibition. In fact, on 
behavioural tasks in which participants are instructed to either refrain from reaching, or reach 
away from a target when it appears, the SLR remains directionally tuned to the target (Wood et 
al., 2015; Gu et al., 2016; Atsma et al., 2018). In this way, regardless of task instruction, the 
initial burst of muscle activity drives the arm towards the target. Consequently, in situations in 
which the participant reaches in the opposite direction (i.e., anti-reach), there is a positive 
correlation between SLR magnitude and reach reaction time, as the arm must overcome that 
initial force driving the muscle towards the target before it initiates a reach in the opposite 
direction (Gu et al., 2016).  Interestingly, there is some influence of contextual factors on the 
SLR, as evidenced by partial suppression of the SLR on anti-reach trials in healthy participants 
(Gu et al., 2016). Relative to the magnitude of the SLR when participants reach towards a target 
(i.e., pro-reach), the magnitude of the SLR preceding anti-reaches is dampened in favour of 
behavioural flexibility. Despite its short latency and seemingly automatic nature, this suggests 
the presence of nodes within the circuitry governing SLRs that convey information about 
planned reach trajectory, and modulate SLR magnitude, but not latency or direction, accordingly. 
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SLRs are evidently modulated differently than volitional reaches, but the neural substrates 
involved in regulating this fast visuomotor pathway remain unclear.   
 
1.2.4 Neural Substrates of SLR Generation and Modulation   
 
The extremely short, stimulus-locked latency and directional tuning towards a visual 
stimulus, rather than the instructed movement direction, suggests the neural pathway that 
generates SLRs is separate from the corticospinal pathway that generates volitional movements. 
This is further supported by ongoing studies in our lab that are finding the SLR is robustly intact 
in PD patients, despite the significant effects of the disease on voluntary movement and 
movement-related EMG activity. The SLR likely shares the same neural circuitry as short-
latency movement corrections performed mid-reach (Kozak et al., 2019), which are also 
preserved in PD, as described above (Merritt et al., 2017).   
Studies seeking to further elucidate the neural circuitry involved in fast visuomotor 
responses have manipulated features of the stimuli used to elicit SLRs and online corrections, to 
identify attributes that preferential evoke this pathway. SLRs are more prevalent on tasks with 
moving targets than static targets (Kozak et al., 2020), and stronger in response to higher contrast 
target stimuli (Wood, 2015; Kozak 2021). Additionally, Kozak and colleagues’ (2019) 
systematic manipulation of the spatial frequency of the visual target revealed more prevalent, and 
shorter-latency SLRs towards targets with low spatial frequencies (0.15, 0.3, 0.6 cpd) compared 
to high spatial frequencies (1.11, 1.6, 2.22 cpd). As expected, the latency of online corrections is 
also shorter in response to the low spatial frequency targets (Veerman et al., 2008; Marino et al., 
2012; Kozak et al., 2019). Together, these results provide important information on the nature of 
the first wave of muscle recruitment, which evidently carries information about the location, but 
not detailed information about the identity of the stimulus. These findings lend support for the 
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hypothesized role of the superior colliculus (SC) in generating the SLR, given the broad 
literature documenting modulation of neural activation in the SC by varying the luminance 
contrast, spatial frequency, and motion of the visual stimulus, in the same way that the SLR is 
modulated (Schneider & Kastner, 2005; Li & Basso, 2008; Marino et al., 2012; Chen et al., 
2018). 
The SC is a phylogenetically well-preserved oculomotor structure in the midbrain that 
integrates multi-modal incoming sensory information from the environment and translates it into 
efferent orienting motor commands (Corneil et al. 2002, 2008; Rezvani & Corneil, 2008; Song et 
al. 2011, 2015; Gandhi & Katnani, 2016; Cooper & McPeek, 2021). The superficial layer of the 
SC receives visual information directly from the retina, and indirectly through the retino-
geniculo-cortical pathway; and the intermediate and deep layers facilitate the transformation 
from visual input to motor commands (Lane et al., 1973; Grantyn and Grantyn 1982; Werner, 
1993; Werner et al., 1997; May, 2006). The SC is the head of the tecto-reticulospinal tract, and 
projects through the premotor bundle to the reticular formation. Although predominately known 
for its role in generating saccadic eye movements, the SC is integral to orienting the head and 
limbs towards salient stimuli and has more recently been found to play a broader role in guiding 
behaviour. Werner (1993) discovered a subset of neurons in the deep layers of the SC and the 
underlying reticular formation of non-human primates that produce action potentials before, and 
during reaching arm movements. This activity was temporally correlated to EMG activity in 
proximal limb muscles (Werner et al., 1997; Stuphorn et al., 2000). Importantly, this subset of 
neurons did not display saccade-related activity, suggesting a functionally distinct population of 
SC neurons associated with limb control. Furthermore, functional magnetic imaging (fMRI) 
investigation has found reach-related activity in the contralateral SC to the reaching arm in 
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humans (Himmelbach et al., 2013), and electrical microsimulation of the SC and reticular 
formation elicits arm movements in non-human primates (Philip and Hoffman, 2014). Together, 
these findings demonstrate the role of the SC in coordinating stimulus-driven recruitment of 
proximal limb muscles via the tecto-reticulospinal tract and make the SC a likely candidate for 
the neural substrate of the SLR. 
Additional evidence supporting the role of the SC in SLR generation and modulation 
comes from Gu et al. (2018), who investigated the frame of reference of the directional tuning of 
the SLR by dissociating the starting position of the hand and gaze relative to the stimulus. It was 
found that the SLR is generated in a hand-centric manner, meaning that it drives the arm in the 
direction of the stimulus relative to where the hand is positioned, not relative to where the eyes 
are fixated. This suggests that visual information about the location of the target is integrated 
with sensory information about the position of the hand to dictate the directionality of the motor 
burst. Importantly, a subset of neurons in the SC are also activated in a hand-centric, rather than 
a gaze-centric, manor in response to visual stimuli (Stuphorn et al., 2000; Song et al., 2011).  
Comparably to the SLR, a portion of SC reach-related neural activity in the SC is directionally 
tuned to the location of the target, regardless of the direction of the reach. These findings suggest 
that this subset of SC neurons generate stimulus-driven motor signals related to the general 
location of the automated reaching goal, rather than control of the reach kinematics, which aligns 
with the nature of the SLR (Cooper and McPeek, 2021).  
An extensive body of literature describes the SC as the site of integration for converging 
signal pathways from the cortex and midbrain, which serve to modulate fast visuomotor 
responses. One of the most critical modulatory pathways converging on the SC comes from the 
substantia nigra pars reticulata (SNr), the output region of the basal ganglia (BG) (Hikosaka et 
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al., 2000; Shires et al., 2010; Watanabe & Munoz, 2011; Coe & Munoz, 2017). Much of what we 
know about SC modulation via the BG comes from studies of saccadic eye movements, which 
can be used to predict the modulatory mechanisms governing the SLR. The SNr provides 
continuous tonic inhibition to both the contralateral, and ipsilateral SC via GABAergic output 
(Karabelas & Moschovakis, 1985; Behan et al., 1987; Bickford & Hall, 1992; Jiang et al., 2003; 
Liu & Basso, 2008). Transient cessation of these inhibitory post-synaptic potentials disinhibits 
saccade-generating neurons, and initiates eye movements. Therefore, the BG modulate saccadic 
eye movements by adjusting the inhibitory activity imposed on the SC by the SNr. The DS, 
comprised of the caudate nucleus (CN) and putamen, accomplishes this by balancing activity 
through the direct and indirect pathways, which are generally known to facilitate and inhibit 
motor output respectively (described in detail above).  
Regulation of the direct and indirect pathways by the DS is critical for response selection 
between automatic and volitional oculomotor commands (Parent & Hazrati, 1995; Smith et al., 
1998; Hikosaka et al., 2000; Nakano et al., 2000; Sato et al., 2000a; Kita, 2007). Watanabe and 
Munoz (2009) reported three distinct populations of neurons in the CN that are differentially 
activated during the pro/anti-saccade task in non-human primates using single neuron recordings: 
neurons 1) active before contralateral pro-saccades and ipsilateral anti-saccades (i.e., always 
tuned to the location of the stimulus), 2) active before contralateral volitional saccades regardless 
of stimulus direction, and 3) active before ipsilateral anti-saccades  (Watanabe & Munoz 2009). 
Pro/Anti-saccade trials and left/right presenting stimuli were randomly interleaved throughout 
the study. Preceding the execution of an anti-saccade, the first and second populations are 
proposed to stimulate the direct pathway to the SNr, thereby promoting automatic stimulus-
driven, and volitional saccades respectively. When an anti-saccade instructional cue is given 
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before target onset, the preparatory activity in the neurons driving volitional saccades is more 
active than when a pro-saccade cue is given, to compensate for the competing stimulus-driven 
response. This heightened preparatory activity is not seen preceding trials when subjects make a 
faulty saccade toward the stimulus. To resolve the conflict between these two signals driving 
saccades in opposite directions, the third population is proposed to activate the indirect pathway 
and selectively inhibit the stimulus-driven response, thus preventing initiation of an incorrect 
saccade towards the stimulus in favour of the voluntary command. Therefore, Watanabe and 
Munoz suggest that successful performance of an anti-saccade requires sufficient activation of 
the voluntary response via the direct pathway, and complementary inhibition of the automatic 
response via the indirect pathway to overcome the stimulus-driven signal. Consequently, 
stimulus-driven saccade responses are less reliant on the BG than controlled/volitional eye 
movements.   
These results can help explain the replicated finding that volitional, memory-guided 
saccades are impaired, but automated stimulus-driven saccades are intact and often disinhibited 
in PD (Fischer & Weber, 1993; Briand et al., 1999; Chan et al., 2005; Cameron et al., 2010). The 
underlying mechanism of this phenomenon is not yet clear, however a prominent hypothesis is 
that because of delayed reaction times of voluntary movement and hypoactivity of the dorsal 
lateral prefrontal cortex (dlPFC), a critical structure in the preparation of voluntary movement, 
the delayed initiation of the anti-saccade allows more time for the SC to be triggered by visual 
signals from the stimulus (Dagher & Nagano-Saito, 2007; Cameron et al., 2009; Cameron et al., 
2010). Therefore, in PD patients the voluntary signal might not be strong or fast enough to elicit 
a voluntary command before the stimulus-driven response is triggered by visual input from the 
retina, though more research in this area is needed. Another possible explanation is that an intact 
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compensatory cerebellar pathway to the intermediate layers of the colliculus allows visually 
guided responses to bypass the dysfunctional BG (Roldan & Reinoso-Suarez, 1981; Glickstein & 
Stein, 1991; Westby et al., 1994).  
Given the important modulatory role of the BG on the SC, and the resulting impairments 
on tests of oculomotor control, it is expected that BG dysfunction will disrupt contextual 
modulation of the SLR. Although there is ample evidence for the role of the SC in the generation 
of the SLR, the neural substrate responsible for attenuating the magnitude of this response 
according to task instructions remains unclear. By studying the SLR in patients with PD, we aim 
to investigate the role of the BG in this process.   
 
1.3 The Present Study  
 
The purpose of this study is to address the existing gap in knowledge regarding the effect 
of the pathology of Parkinson’s disease (PD) on the modulation of the fast visuomotor pathway 
for reaching. Although there is growing evidence of the preservation of rapid visuomotor 
responses, including the stimulus-locked response (SLR), in patients with PD, it remains unclear 
whether the ability to modulate the SLR is equally intact. This study aims to build on the recent 
finding from our lab that the SLR is preserved in patients with PD by assessing the effect of 
contextual control of this response. Although Kozak found no differences between PD patients 
and healthy controls in the ability to modulate the magnitude of the SLR on Anti-reach compared 
to Pro-reach trials, participants had > 1500 ms to consolidate the instructional cue of each trial 
before target onset. Given that this finding is unexpected in the context of the current literature, 
this task might have allowed participants too much time to prepare to reach away from the 
stimulus to detect differences in SLR modulation between groups. Therefore, the current study 
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aims to challenge the participants by only providing the Anti-reach or Pro-reach instructional cue 
either 500 ms or 1000 ms before the target emerges. This will reduce the time available for pre-
emptive, top-down inhibition on the fast visuomotor pathway to modulate SLR magnitude in 
favour of the appropriate goal-driven response (Coe & Munoz, 2017). By measuring the SLR 
magnitude on upper limb muscles during an anti/pro-reach task with varying instruction times 
both off and on dopamine (DA) medication, this study aims to 1) elucidate the effect of DA 
deficiency in the BG of PD patients on contextual modulation of the SLR and 2) to determine the 
effect of instruction time on SLR modulation in patients with PD. 
This study will provide novel insight into the role of the dorsal striatum (DS) on the 
modulation of the earliest phase of muscle recruitment in reaching. Recording muscle 
activity with EMG allows us to detect changes in muscle activity with greater temporal 
resolution than what other studies in PD patients have been able to achieve using measures of 
kinematic events alone. Theoretically, different patterns of early muscle recruitment can produce 
identical actions, complicating inferences about muscle recruitment from measures of reaction 
times or error rates. The use of EMG circumvents the confounds created by the arm’s inertia, 
enabling clearer assessment of the command issued to the motor periphery. Importantly, this 
design also allows enough temporal precision to dissociate the effects of PD on the modulation 
of the fast visuomotor system from the effects of PD on the subsequent muscle recruitment 
driving the voluntary response.    
We hypothesized that BG function is critical for the contextual control of the SLR, and 
that PD patients would demonstrate impaired inhibitory modulation of this response on the 
anti/pro-reach task. Specifically, we predicted that while off DA medication, PD patients would 
generate SLRs of equal magnitude on Anti-reach trials and Pro-reach trials. This would suggest a 
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deficit in the modulation of the SLR, as healthy participants generate smaller SLRs on Anti-
reach trials compared to Pro-reach trials. The difference in magnitude of the SLR on Anti-reach 
trials compared to Pro-reach trials can be used as a measure of contextual control. Conversely, 
we predicted that while on dopaminergic medication, patients would generate SLRs of 
smaller magnitude on Anti-reach trials and demonstrate the same level of inhibitory control as 
healthy participants. Furthermore, we expected that the deficit in contextual control in the PD 
group would be most apparent on trials with only 500 ms of instruction time compared to trials 
with 1000 ms of instruction time, as they are required to integrate the contextual information into 
the visuomotor circuitry more quickly, making the task more difficult. Owing to research 
restrictions at Western University during the COVID-19 pandemic, we were unable to collect 
data from age-matched healthy control participants. Therefore, this thesis will examine the 
performance of PD patients on and off their medication to investigate the effect of dorsal 
striatum function on SLR modulation. Data collection from control participants will be 
completed when it is approved to do so by the university.   
Chapter 2 
2 Methods  
 
2.1 Participants  
 
All participants were recruited by phone from the Movement Disorders Database at 
London Health Sciences Centre. Ten participants who had received a clinical diagnosis 
of idiopathic Parkinson’s disease (PD) from a movement disorder neurologist were enrolled in the 
study (5 females, 5 males). Restrictions on research at Western University in response to the 
COVID-19 pandemic prevented recruitment of the targeted sample size of 20 PD patients and 20 
age-matched healthy controls. However, the manipulation of dopamine (DA) medication within 
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the participants allows for exploratory investigation into the role of DA in fast visuomotor 
response for the purpose of this thesis. A larger sample of PD patients and a healthy control 
group will be tested for this study when participant testing at Western University resumes. All 
participants were taking previously prescribed dopaminergic medication to manage their PD 
symptoms at the time of recruitment and were responsive to their current dose (Levodopa dose 
equivalency: M=624.80 mg, SD=403.23). Exclusion criteria included a diagnosis of any 
neurological disorder besides PD; a history of alcohol or drug abuse, psychiatric disorders, 
dementia, or hallucinations; uncorrected visual deficits including colour blindness; a history of 
deep brain stimulation treatment; and injuries or conditions preventing normal movement of the 
right arm. Participants were screened over the phone and filled out a Health and Demographics 
questionnaire before participating (Appendix A). Participants provided written, informed consent 
(Appendix B) at the time of their first session in accordance with the Declaration of Helsinki 
(1991), and all procedures were approved by the Health Sciences Research Ethics Board of 
Western University (Appendix C).  All participants were compensated $15/h for a total of $75.00 
for their time spent participating in this study.  
Participants completed two identical experimental sessions at the Brain and Mind 
Institute at Western University in London, Ontario, a minimum of 24 h apart. One session was 
completed in the ON condition, in which participants were instructed to take their regular 
medication as prescribed by their neurologist. The other session was completed in the OFF 
condition, in which participants were asked to refrain from taking their dopaminergic or DA 
agonist medication before the test.  Participants stopped taking DA agonists, such as 
pramipexole (Mirapex), 16-18 h before the testing session, and stopped taking DA replacement 
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medication, such as levodopa-carbidopa (Sinemet), 12-14 h before the testing session. The order 
of ON and OFF sessions was counterbalanced across participants to eliminate the risk of  
confounding order effects on task performance. The Movement Disorders Society-Unified 
Parkinson’s Disease Rating Scale Motor Subscale (MDS-UPDRS III) was employed at both 
testing sessions to evaluate PD symptom severity and verify the effectiveness of the 
dopaminergic medication manipulation.   
2.2 Demographic, Cognitive, and Affective Assessments   
 
At each experimental session participants completed several questionnaires to assess 
demographic, cognitive (Table 1), and affective (Table 2) measures to gain insight into the 
characteristics of the patient sample and perform comparisons across medication states when 
applicable. All cognitive assessments were completed by patients in the ON state.  In addition to 
the questionnaires described in detail below, participants completed the Epworth Sleepiness Scale 
(Appendix D; Johns, 1991), Barratt Impulsiveness Scale (Appendix E; Barratt et al., 1975), 
Oxford Happiness Questionnaire (Appendix F; Hills & Argyle, 2002), Questionnaire for 
Impulsive-Compulsive Disorders in Parkinson’s Disease (Appendix G; Weintraub et al., 2011), 
Verbal and Category Fluency Test (Appendix H), and Sensation Seeking Scale (Appendix I; 
Zuckerman et al., 1964). As these were collected for the purpose of comparison between patients 
with Parkinson’s disease (PD) and healthy controls, they were not analyzed for this thesis, but 
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 Table 1 Demographic and clinical information from participants (n=10); N-FOG = New Freezing of 
Gait Questionnaire, higher score indicates more severe symptoms; UPDRS = Movement Disorders 
Society Unified Parkinson Disease Rating Scale, higher score indicates more severe symptoms; MoCA 
= Montreal Cognitive Assessment, higher score indicates better performance; AMNART = American 
version of the Nelson Adult Reading Test, higher score indicates higher estimated intelligence  
 
Table 2 Affective questionnaire data (n=10); BDI = Beck Depression Inventory II, higher score indicates 
higher incidence of depressive symptoms; BAI = Beck Anxiety Inventory, higher score indicates higher 
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2.2.1 New Freezing of Gait Questionnaire (N-FOG) 
  
The N-FOG (Appendix J; Nieuwboer et al., 2009) was used to evaluate the severity of 
freezing of gait, a symptom of PD associated with disease severity. Freezing of gait episodes are 
defined as: “experiencing the feeling that the feet are transiently glued to the floor while trying to 
initiate walking, making a turn, or when walking through narrow spaces or crowded 
places”. Participants who did not report freezing of gait (n=5) received a score of 0, and those 
who did report this symptom (n=5) received a score between 1 and 29, with higher scores 
indicating higher frequency and severity of FOG episodes.   
 
2.2.2 Montreal Cognitive Assessment (MoCA) and American Version of the Nelson Adult 
Reading Test (AMNART)  
 
Participants completed the MoCA (Appendix K; Nasreddine et al., 2005) and AMNART 
(Appendix L; Grober et al., 1991) to assess cognitive ability and premorbid verbal IQ 
respectively. The MoCA is a standard test used to screen for cognitive impairment by assessing 
short-term memory, attention, verbal fluency, executive functioning, and visuospatial abilities 
with a variety of short tasks (e.g., drawing a clock, recalling a list of words, repeating a 
sentence). Higher scores indicate higher cognitive functioning, and a cutoff of at least 23/30 
points was used as exclusion criteria in accordance with the suggested cutoff for older adults 
reported by Carson et al. (2018). The AMNART is a reading test developed to estimate IQ from 
the number of words read aloud correctly from a 50-item list, and the participant’s years of 
formal education: (118.2-0.89(errors)+0.64(years of education)). A higher score indicates higher 
estimated verbal intelligence.   
 
2.2.3 Bond and Ladder Visual Analogue Mood Scale (BL-VAS)  
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The BL-VAS was used to measure changes in mood over the period of the session 
(Appendix M; Bond & Ladder, 1974). The questionnaire consists of 16 mood scales (horizontal 
lines) with opposing feelings at either end (e.g., calm and excited). Participants were instructed 
to draw a vertical line through each scale to indicate their current state based on the relative 
proximity of the line to each word. Sub scores were calculated for alertness, calmness, and 
contentedness. Values in Table 2 are reported as the difference between the BL-VAS score at the 
beginning and end of the session on each testing day (negative values indicate a decrease over 
time). Given the potential fatiguing effect of dopamine (DA), this measure was used to 
ensure that changes in these measures over the course of the session did not affect participants’ 
performance differently in the ON vs the OFF condition, which is confirmed by the values in 
Table 2.   
 
2.2.4 Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), 
and Starkstein Apathy Scale (SAS)  
 
Approximately 20-40% of patients with PD experience depression, anxiety, and apathy. 
These affective symptoms were assessed with the BDI-II (Beck et al., 1996), BAI (Beck et al., 
1988) and SAS (Appendix N; Starkstein et al., 1992) at the end of each session. Higher scores 
indicate higher self-reported incidence of each trait. BDI-II and BAI scores range from 0-63. 
BDI-II scores are interpreted using the following guidelines: minimal depression 0-13, mild 
depression 14-19, moderate depression 20-28, severe depression ≥29. The BAI scores are 
assessed as follows: minimal anxiety 0-7, mild anxiety 8-15, moderate anxiety 16-25, severe 
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2.3 Behavioural Task  
 
Participants performed a behavioural task using a KINARM end-point robot (BKin 
Technologies, Ltd.), which allows the user to control a real-time cursor on a screen by generating
planar reaching movements with a manipulandum beneath the screen. The paradigm used in this 
study was a modified version of the Emerging Target paradigm described in Kozak (2020). This 
task has been successful at reliably eliciting stimulus-locked responses (SLRs) in upper limb 
muscles in previous studies (Kozak et al., 2021; Contemori et al., 2021). At the beginning of each 
trial, a target appeared at the top of the screen (Figure 2).  The target then descended behind 
a visual occluder for 1000 ms before emerging in continuing motion below the occluder at either 
the right or left outlet.  As soon as the target emerged from the occluder, in the Pro-reach trials, 
participants used their right arm to quickly reach toward the target, whereas in the Anti-reach 
trials, they used their right arm to quickly reach away from the target as quickly as they 
could. This instruction was conveyed to participants by the colour of a small fixation square at 
the bottom of the occluder, on which participants were asked to fixate while the target was 
behind the barrier. In all trials, the fixation square was initially coloured grey, and prior to target 
emergence, turned red on Anti-reach trials and green on Pro-reach trials. As a novel extension to 
a similar paradigm previously used in the lab, the fixation point changed colour either 500 ms 
or 1000 ms before the target emerged. In this way, we could identify differences in the time 
required for task instruction to modulate rapid visuomotor responses while patients were off and 
on medication. If participants reached in the wrong direction according to task instruction, the 
words “Wrong Way” appeared, and if the participant reached in the correct direction the words 
“Hit” appeared. Conversely, if no response was detected before the end of the trial, the word 
“Missed” appeared on the screen. The task consisted of five blocks of 104 trials. Anti- and Pro-
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reach trials, left-ward and right-ward targets, and trials with 500 ms and 1000 ms of instruction 
time, were randomly assorted throughout each block of trials. In total there were 65 trials of each 
of the eight different trial types:  Anti/Left/500 ms, Anti/Left/1000 ms, Anti/Right/500 ms, 
Anti/Right/1000 ms, Pro/Left/500 ms, Pro/Left/1000 ms, Pro/Right/500 ms, Pro/Right/1000 ms.  
 
2.4 Data Acquisition  
 
The emerging target task was programmed in MATLAB/Simulink (Mathworks, Inc.) 
and Dexterit-E (BKin Technologies, Ltd.) for the KINARM end-point robot. During the task, two 
single-differential surface electrodes were placed on the right pectoralis major muscle. One was 
placed on the sternal head, and one was placed more laterally on the clavicular head.  This 
muscle was chosen because it is heavily activated during planar cross body reaches, it is easily 
accessible on participants, and it reliably expresses stimulus-locked responses (SLRs; Kozak et 
Figure 2 Schematic of the KINARM screen through time during pro-reach and anti-reach trials of the 
Emerging Target paradigm. The participant's hand controls the white curser at the bottom. 
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al., 2020; Kozak et al., 2021). Off-line analysis of the signal from the two electrodes was 
compared, and the electrode with the best signal-to-noise ratio across both days was selected 
for further analysis for each participant. In all cases, whichever recording (e.g., sternal or 
clavicular head) chosen on the first day was also chosen on the second day. EMG data were 
recorded with the Delsys Inc. Bagnoli-8 system at 1 kHz and amplified by 1000 (Bagnoli-8 
System, Delsys Inc., Boston, MA). This system uses a band-pass filter to filter the EMG signal to 
between 20 Hz and 450 Hz. Offline, EMG signals were full-wave rectified and smoothed using a 
7 point running average filter prior to further analysis. During the task, a small force was applied 
to the manipulandum to elicit baseline activity in the muscle of interest (5 N right and 2 N 
towards the participant). Because the participant was required to activate his/her muscle to hold 
the cursor centrally at the beginning of each trial, right-ward SLRs and reaches were detectable 
as a decrease in activity relative to baseline. EMG activity was normalized to baseline activity for 
each trial to account for variations in EMG signal across patients and testing days. In addition to 
EMG data, the KINARM system recorded position and kinematic data at 1 kHz from high-
resolution force/torque sensors in the manipulandum. Eye movements were also recorded with 
two EOG surface electrodes placed adjacent to each eye, however the high noise-to-signal ratio 
of most participants’ data rendered the recordings unusable for analysis of eye movement 
reaction times.   
 
2.5 Data Analysis  
 
2.5.1 Data Exclusion   
 
Trial-by-trial data were examined via a customized MATLAB Graphical User 
Interface to exclude obviously atypical trials. Trials were excluded for the following reasons: a) 
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no reach was made, indicating a lack of attempt to follow task instruction, or b) the arm was 
obviously in motion prior to target appearance. Sequences where the subject initially moved in 
the incorrect direction before moving in the correct direction were retained.  Trials were 
excluded from analysis if the reaction time was shorter than 130 ms or longer than 500 ms based 
on the time at which the participant reached 5% of the peak velocity, to eliminate a) movement 
resulting from anticipatory activity, b) tremor in the starting position, or c) aberrantly delayed 
reactions due to inattention. Together, these criteria screened out 12.9% of trials (OFF: 13.1%; 
ON: 12.8%), with 12.8% of trials excluded based on reaction time cutoffs.   
 
2.5.2 Planned Statistical Analysis   
 
To investigate the effects of Instruction Time (500 ms vs 1000 ms), Trial Type (Anti-
reach vs Pro-reach), and Medication State (OFF vs ON) on our selected dependent variables 
described below, linear mixed models were used to quantify main effects and interactions. Linear 
mixed models were chosen over repeated-measures analysis of variance (ANOVA) because of 
their ability to account for missing data (e.g., if a participant expressed an SLR in one but not 
another condition). Unlike ANOVAs, linear mixed models do not use list-wise deletion in the 
case of missing data points which allowed us to maximize the power and reduce the bias of our 
analysis. The Satterthwaite method was applied to estimate degrees of freedom and generate p-
values for the mixed model analyses. Instruction Time, Trial Type, and Medication State were 
specified as fixed effects, and participant ID was specified as a random effect in the linear mixed 
models. Post-hoc orthogonal contrasts with the Bonferroni correction method for multiple 
comparisons were used to investigate significant interactions between predictor variables. Data 
processing was done in MATLAB (R2014b), and statistical analyses were performed in JASP.   
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2.5.3 Behavioural and Kinematic Analysis  
 
Several behavioural parameters were assessed. Reaction time (ms) was calculated as the 
time at which the participant’s arm reached 5% of the peak velocity following target onset. Only 
correct trials were included in reaction time calculations. For error rate calculations, any trial in 
which a participant’s initial arm movement went in the incorrect direction in reference to the task 
instruction was considered an error. Error rates (%) are represented as a percentage of total trials 
of that type in the respective medication state. There are roughly 130 trials of each of the four 
trial types in each medication state: 1) Anti-reaches with 500 ms of instruction, 2) Anti-reaches 
with 1000 ms of instruction, 3) Pro-reaches with 500 ms of instruction, 4) Pro-reaches with 1000 
ms of instruction.  
The peak velocity (m/s) for each trial was calculated from the first segment of the 
reaching movement to eliminate confounds created by including corrective, or secondary 
movements in this analysis. Time to peak velocity (ms) was used as a construct of acceleration 
and was calculated as the time from the reaction time, or the point at which the participant’s arm 
reached 5% of its peak velocity, to the point at which the arm reached peak velocity on each 
trial. Movement duration (ms) was quantified as the time from the reaction time to the point at 
which the velocity of the arm fell below 5% of the peak velocity.  
 
2.5.4 EMG Analysis  
 
The stimulus-locked response (SLR) is the first burst of muscle activity that drives the 
arm towards a visual stimulus within 80-120 ms after stimulus onset. Figure 3 illustrates the 
EMG activity of a representative participant in the OFF condition. The SLR is the visible change 
in activity that consistently appears around 100 ms. The presence of the SLR was identified 
using a time series receiver operating characteristic (ROC) curve analysis. ROC curves quantify 
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the probability that an ideal observer could discriminate between leftward and rightward stimuli 
conditions from EMG activity alone. ROC curves were constructed for averaged EMG activity at 
each ms from 50 ms before, to 300 ms after target onset. An area under the curve (AUC) of 0.5 
represents chance-level discrimination, and an AUC value of 1 represents perfect discrimination 
(Green & Swets, 1966). SLR onset was identified as the time point at which the AUC value 
surpassed a discrimination threshold of .65 for a minimum of 5 of the subsequent 8 ms. Figure 4 
shows averaged EMG activity from a single representative participant in the OFF condition, and 
the corresponding plot of time series ROC values used to detect SLR onset. If the ROC curve did 
not pass this threshold between 80 ms and 120 ms from target onset, an SLR was not detected, 
and that participant was not included in the latency analysis for the respective trial type 
(Contemori et al., 2020). The discrimination time was calculated for each trial type and used to 
analyze SLR prevalence and magnitude. Trials in which the participant went in the correct 
direction or went ≤ 50% of the distance of their average reach in the wrong were included in the 
analysis of SLR prevalence and latency.   
For analysis of SLR magnitude, SLR onset was determined by finding the discrimination 
time for all averaged pro-reach trials in each medication state (OFF and ON) for each participant. 
This discrimination time was used for the analysis of SLR magnitude on all trial types (Anti- and 
Pro-reach) to ensure that EMG activity was being analyzed in a consistent time window to allow 
for comparison between Anti- and Pro-reach trials. SLR magnitude was calculated as the integral 
of the difference curve between the averaged EMG activity on leftward and rightward reaches 
for each trial type, from the time of SLR onset to 30 ms after SLR onset.  
The SLR modulation index was calculated as a measure of the suppression of the SLR on 
Anti-reach trials relative to the SLR on Pro-reach trials: (Pro-Anti)/(Pro+Anti). This index 
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ranged from -1 to 1. An index of 1 would indicate complete suppression of the SLR on Anti-
reach trials, an index of 0 would indicate SLRs of equal magnitude on Anti-reach and Pro-reach 
trials, and an index of –1 would indicate complete suppression of the SLR on Pro-reach trials.   
To investigate the magnitude of the SLR as a function of the magnitude of movement-
related activity (%), it was analyzed as a percentage of the magnitude of the EMG burst 
preceding movement onset for the respective trial type. The movement-related motor burst was 
identified as the peak in the difference curve of averaged EMG activity between leftward and 
rightward movements in the period between 100 ms and 0 ms before movement onset. 
The magnitude of this motor burst was calculated as the integral of the difference curve from 15 
ms before, to 15 ms after the peak.   
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Figure 3 EMG colour plots of a single representative participant on pro- and anti-reach trials 
with left and right ward appearing stimuli. White squares indicate reaction time of the correct 
reach for each trial. The SLR appears between 80 ms and 120 ms from target onset, which can 
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Figure 4 Averaged EMG activity of a single, representative participant in the OFF condition on pro-reach 
trials across time (A). The corresponding values of the area under the ROC curve comparing left-ward and 
right-ward reaches across time (B). SLR onset was detected when the value surpassed .65 for 5ms. 
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3  Results 
 
The aim of our analyses was to investigate the effects of Instruction Time, Trial Type, 
and Medication State on a number of behavioural, kinematic, and EMG measures. A paired-
sample t-test (t(8) =-4.28, p=.001) revealed that MDS-UPDRS scores were significantly higher 
in the OFF condition compared to the ON condition (OFF: M=43.3, SE=4.21, SD=11.9; ON: 
M=32.2, SE=4.18, SD=11.8), indicating that the manipulation of dopaminergic medication had 
the expected beneficial effects on the primary motor symptoms of Parkinson’s disease (PD). We 
expected this would also be evident in the error rate and kinematic features of voluntary reaches 
on the behavioral task, but would have no effect on the magnitude or latency of the stimulus-
locked response (SLR). We also predicted that Medication State would have a significant effect 
on SLR modulation, such that there would be less modulation of the SLR on Anti-reach trials in 
the OFF condition. This section will outline the results of behavioural and kinematic analyses, 
followed by the results of the EMG data, focusing on the SLR. Although the kinematic features 
of participants’ reaches consistently trended in the expected direction between medication states, 
the study was likely underpowered to detect significant differences. There were no reliable trends 
in the effect of dopamine (DA) on SLR generation, as seen in the consistency of SLR prevalence, 
latency, and magnitude between medication states. Surprisingly, despite the significant effect of 
Instruction Time on SLR modulation, there was no evidence of an effect of Medication State on 
SLR modulation, even with only 500 ms of instruction time when the task was most challenging. 
Though there were no consistent trends of medication effects on the magnitude of the SLR, there 
was a trend toward the expected positive effect of dopaminergic medication on the magnitude of 
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movement-related activity, suggesting a differential effect of DA on different stages of muscle 
recruitment. 
 
3.1 Behavioural and Kinematic Analysis 
 
3.1.1 Reach Reaction Time 
 
Reach reaction time was measured as the time from target onset to the time at which the 
arm reached 5% of its peak velocity. The linear mixed model analysis revealed a significant main 
effect of Instruction Time on reach reaction time [F(1,10)=101, p<.001]. Participants had 
significantly longer reaction times with 500 ms of instruction time relative to 1000 ms of 
instruction time (Figure 5a; 500 ms: M=259, SE=7.21, SD=45.6; 1000 ms: M=230, SE=5.82, 
SD=36.8). This indicates that when participants had less time to consolidate the instructional cue, 
they took longer to initiate their response, suggesting the manipulation of instruction time was 
successful at making the task more cognitively taxing for participants. There was also a 
significant main effect of Trial Type [F(1,9)=74.6, p<.001]. Participants had significantly 
prolonged reaction times on Anti-reach trials than on Pro-reach trials, which is expected on this 
task based on previous results from our lab, as participants must overcome the initial impulse to 
reach towards the target before moving the arm in the opposite direction on Anti-reach trials 
(Anti-reach: M=274, SE=36.8, SD=16.6; Pro-reach: M=215, SE=4.36, SD=27.6). There was a 
significant interaction between Instruction Time and Trial Type [F(1,45)=11.8, p=.001], which 
indicated that participants had significantly longer reaction times with 500 ms of instruction than 
with 1000 ms of instruction on both Anti-reach (500 ms: M=291, SE=8.31, SD=36.6; 1000 ms: 
M=257, SE=6.54, SD=28.5; p<.001) and Pro-reach trials (500 ms: M=227, SE=6.38, SD=27.8; 
1000 ms: M=204, SE=5.15, SD=22.5; p<.001), and this difference was greater on Anti-reach 
trials. There was no significant main effect of Medication State on reaction time [F(1,9)=.041, 
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p=.842], and the mean reaction time was very similar off and on medication (OFF: M=245, 
SE=7.03, SD=44.5; ON: M=244, SE=6.87, SD=4304). There were no other significant 
interactions between predictor variables (p>.05).  
 
Figure 5 A) Mean (SEM) reach reaction times on pro- and anti-reaches B) Mean (SEM) 
directional error rate on pro- and anti-reaches C) Mean (SEM) peak velocity attained by the 
reaching arm on pro- and anti-reaches D) Mean (SEM) time taken for the reaching arm to reach 
peak velocity on pro- and anti-reaches E) Mean (SEM) movement duration on pro- and anti-
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3.1.2 Error Rate 
 
Error rate was measured as the percentage of trials in which the participant made a 
directional error relative to the instructional cue (i.e., the participant reached towards the target 
on Anti-reach trials or away from the target on Pro-reach trials). Participants had more difficulty 
with the task on trials with shorter instructional cues, especially on Anti-reach trials (Figure 5b). 
There was a significant main effect of Instruction Time on error rate [F(1,14)=39.8, p<.001], as 
participants made significantly more errors with 500 ms of instruction relative to 1000 ms of 
instruction (500 ms: M=20.1, SE=2.22, SD=14.0; M=10.6, SE=1.52, SD=9.61). There was also a 
significant main effect of Trial Type [F(1,10)=109, p<.001]. Participants made more errors on 
Anti-reach trials than on Pro-reach trials (Anti-reach: M=24.7, SE=1.78, SD=11.3; Pro-reach: 
M=6.01, SE=.867, SD=5.48). There was a significant interaction between Instruction Time and 
Trial Type [F(1,50)=.547, p=.023]. Post-hoc orthogonal contrasts with the Bonferroni correction 
method revealed that participants made significantly more errors with only 500 ms of instruction 
compared to 1000 ms of instruction on both Anti-reach trials (500 ms: M=31.0, SE=2.51, 
SD=10.9; 1000 ms: M=18.4, SE=1.73, SD=7.52; p=.002) and Pro-reach trials (500 ms: M=9.15, 
SE=1.34, SD=5.85; 1000 ms: M=2.87, SE=.596, SD=2.60; p<.001). There was no significant 
main effect of Medication State [F<1] on error rate, although participants made slightly more 
errors while off medication than while on medication (OFF: M=15.8, SE=2.09, SD=13.2; ON: 
M=14.8, SE=2.00, SD=12.7). Figure 5b illustrates that the expected trend towards improved 
performance while on medication is most evident with only 500 ms of instruction, when the task 
is more challenging. This suggests that when participants had less time to consolidate the 
instructional cue before reacting they demonstrated a slight deficit in performance when off their 
medication, but this did not reach significance. There were no other significant interactions 
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between predictor variables (p>.05). These results highlight the clear effect of the duration of the 
instructional cue on the participants’ performance. In accordance with the reaction time results, 
these results indicate that the decrease in instruction time from 1000 ms to 500 ms was 
successful at making this task more challenging. Figure 5b illustrates the amplification of the 
negative effect of shorter instruction time on Anti-reach trials, in which the participants must 
reach in the opposite direction of the target by quickly consolidating the instruction to suppress 
the urge to reach towards it.  
 
3.1.3 Peak Velocity 
 
The peak velocity of the reaching arm was calculated to assess the speed at which the 
participants reached towards/away from the target. There was a significant main effect of 
Instruction Time [F(1,9)=7.40, p=.024], indicating participants reached a higher peak velocity 
with 500 ms of instruction time compared to 1000 ms of instruction time (Figure 5c; 500 ms: 
M=.510, SE=.002, SD=.147; 1000 ms: M=.501, SE=.002, SD=.140). This result suggests that 
participants moved more quickly with less time to consolidate the instructional information 
before target onset. This could be explained by the delayed reaction times with 500 ms of 
instruction compared to 1000 ms of instructions: participants must move their arm faster to reach 
the target the later they initiate the reach to compensate for lost time, because the target is in 
constant downward and outward motion from the time of emergence.  There was no significant 
main effect of Trial Type [F(1,9)=4.75, p=.057], although participants reached lower peak 
velocities on Anti-reach trials than on Pro-reach trials, and this effect approached significance 
(Anti-reach: M=.527, SE=.002, SD=.130; Pro-reach: M=.479, SE=.003, SD=.156). This trend 
suggests that participants tend to make slower movements when instructed to reach away from 
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the target than when they are instructed to make a more automated response towards it. There 
was no significant main effect of Medication State on peak velocity [F(1,9)=4.87, p=.055], 
however participants reached a lower average peak velocity while off medication relative to on 
medication, and this effect approached significance (OFF: M =.499, SE=.002, SD=.139; ON: 
M=.512, SE=.002, SD=.148). Although not statistically significant, this trend suggests that 
dopaminergic medication had the expected positive effect on the maximum speed of participants’ 
movements. There were no significant interactions between any of the predictor variables 
(p>.05).  
 
3.1.4 Time to Peak Velocity 
 
The time required for the participants’ arm to reach its peak velocity was used as a 
construct of reach acceleration. There was no significant main effect of Trial Type on the time 
taken to reach peak velocity [F(1,9)=4.38, p=.066], although participants reached peak velocity 
later on Anti-reach trials than on Pro-reach trials (Anti-reach: M=286, SE=1.48, SD=84.7; Pro-
reach: M=275, SE=1.15, SD=73.6). Medication State did not have a significant main effect on 
the time required to reach peak velocity [F(1,9)=1.29, p=.286], although, in-line with the results 
of the analysis of peak velocity, participants reached peak velocity slightly later in the OFF state 
than in the ON state (OFF: M=282, SE=1.27, SD=76.8; ON: M=278, SE=1.32, SD=80.8). This 
indicates that not only do participants tend to reach lower speeds while off dopaminergic 
medication, they also accelerate less quickly in their movement and, in turn, reach their 
maximum velocity later. There was a significant interaction between Medication State and Trial 
Type [F(1,36)=4.96, p=.032]. Post hoc orthogonal contrasts with the Bonferroni correction 
method indicated that participants reached peak velocity significantly later on Anti-reach trials 
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than on Pro-reach trials in the ON condition (Anti-reach: M=289, SE=16.6, SD=72.4; Pro-reach: 
M=273, SE=13.5, SD=58.8; p=.022), but there was no significant difference between Anti- and 
Pro-reach trials in the OFF condition, although the data followed a similar trend (Anti-reach: 
M=291, SE=15.5, SD=67.9; Pro-reach: M=281, SE=13.3, SD=57.9; p=.122). Figure 5 shows that 
this interaction is driven by the short time required to reach peak velocity on Pro-reach trials 
while on dopaminergic medication. There was no significant main effect of Instruction Time on 
time to peak velocity [F(1,9)=1.92, p=.197], however participants reached peak velocity slightly 
later with 500 ms of instruction time relative to 1000 ms of instruction time (Figure 5d; 500 ms: 
M=282, SE=1.31, SD=79.4; 1000 ms: M=278, SE=1.28, SD=78.3). Together with the results of 
the peak velocity analysis, this indicates that with shorter instruction time participants reach a 
higher maximum velocity, but take slightly longer to reach that velocity, compared to trials with 
longer instruction time. There were no other significant interactions between predictor variables 
(p>.05).  
 
3.1.5 Movement Duration 
 
Movement duration was calculated as the time from the reaction time to the time at which 
the velocity of the reaching arm fell below 5% of its peak velocity. There was no significant 
main effect of Instruction Time on movement duration [F<1], and the mean movement duration 
was very similar for trials with 500 ms of instruction time and 1000 ms of instruction time (500 
ms: M=563, SE=2.00, SD=122; 1000 ms: M=565, SE=2.02, SD=124). There was also no 
significant main effect of Trial Type on movement duration [F(1,9)=3.08, p=.106], although 
participants made shorter movements on Anti-reach trials than on Pro-reach trials, indicating that 
participants take longer to complete their reach when instructed to reach away from the target, 
than when they are instructed to reach towards it (Figure 5e; Anti-reach: M=552, SE=2.15, 
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SD=124; Pro-reach: M=574, SE=1.86, SD=121). There was also no significant main effect of 
Medication State on movement duration [F(1,9)=3.29, p=.103], although participants’ movement 
durations were higher while on medication than off medication (OFF: M=571, SE=1.98, 
SD=121; ON: M=558, SE=2.03, SD=125). This trend is consistent with the findings of the 
previous kinematic analyses, as participants tend to accelerate less quickly, reach lower 
velocities, and take more time to complete their reaches in the OFF condition. There were no 
significant interactions between any of the predictor variables (p>.05).  
In summary, the behavioural and kinematic data displayed the expected trends of 
dopaminergic medication effects on movement. Participants made faster and shorter reaches 
while on medication and made fewer errors while on medication on the trials with only 500 ms 
of instruction. The data are congruent with our prediction that having a shorter instruction period 
before target emergence would make the task more difficult. Participants made significantly 
more errors and had longer reaction times with only 500 ms of instruction compared to 1000 ms. 
Trial type had the expected effect on task performance and reach kinematics, as Anti-reaches 
were more difficult and took longer to perform than Pro-reaches. The following section will 
discuss the effects of Instruction Time, Trial Type, and Medication State on the SLR, which 
interestingly, differ from the effects on voluntary movement.  
 
3.2 EMG Analysis 
 
3.2.1 SLR Prevalence and Latency 
 
The stimulus-locked response (SLR) detection analysis was done on the data from four 
different trial types performed in both the OFF and ON state for each participant, for a total of 80 
observations (8 conditions x 10 participants). An SLR was detected in 84% of these cases 
(Figure 6a, 6b). All participants displayed an SLR on at least three of the eight conditions: OFF-
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Anti-500 ms: 90%; OFF-Anti-1000 ms: 50%; OFF-Pro-500 ms: 90%; OFF-Pro-1000 ms: 100%; 
ON-Anti-500 ms: 80%; ON-Anti-1000 ms: 80%; ON-Pro-500 ms: 80%; ON-Pro-1000 ms: 
100%. A Chi-square test indicated that the prevalence of an SLR did not differ between OFF and
ON conditions (X2(1)=.092, p=.762). 
 
 
 Figure 4 shows averaged EMG activity from a single representative participant in the 
OFF condition (4a), and the corresponding plot of time series receiver operating characteristic 
(ROC) curve values used to detect SLR onset (4b). SLR latency was calculated as the time 
between target emergence and SLR onset (Figure 6c). There was no significant main effect of 
Instruction Time on SLR latency [F(1,7)=.402, p=.545], and mean SLR latency was relatively 
consistent with 500 ms of instruction and 1000 ms of instruction (500 ms: M=100, SE=1.51, 
SD=8.81; 1000 ms: M=99.0, SE=1.53, SD=8.81). There was no significant main effect of Trial 
Type on SLR latency [F(1,7)=3.20, p=.117], and again, participants had very similar SLR 
Figure 6 A) SLR prevalence expressed as the percentage of participants expressing an SLR on each 
trial type in the ON condition B) SLR prevalence expressed as the percentage of participants 
expressing an SLR on each trial type in the ON condition C) Mean (SEM) SLR latency relative to 
target onset on pro- and anti-reaches. *p<.05, **p<.001 
A B C 
OFF  1000ms 
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latencies in the Anti-reach and Pro-reach conditions (Anti-reach: M=101, SE=1.80, SD=9.85; 
Pro-reach: M=98.5, SE=1.27, SD=7.71). There was no significant main effect of Medication 
State on the latency of the SLR [F(1,8)=4.39, p=.069], and mean SLR latency was similar while 
off medication and on medication (OFF: M=101, SE=1.74, SD=9.97; ON: M=98.6, SE=1.27, 
SD=7.41l). There were no significant interactions between any of the predictor variables (p>.05). 
Figure 6c demonstrates the consistency of SLR latency across conditions, which is to be 
expected given the time-locked nature of the SLR to stimulus onset, regardless of varying 
reaction times.  
 
3.2.2 SLR Magnitude 
 
The most critical result for testing our hypothesis was the analysis of SLR magnitude. If 
dopamine (DA) input to the dorsal striatum (DS) is involved in the modulation of the SLR, then 
an Instruction Time x Trial Type x Medication State interaction would be expected. However, 
we did not see this in the results, as the magnitude of the SLR in the Anti- relative to the Pro-
reach condition was not influenced by Medication State, regardless of Instruction Time. There 
was a significant main effect of Instruction Time on SLR magnitude [F(1,9)=5.43, p=.044], as 
the mean SLR magnitude was significantly smaller with 500 ms of instruction than with 1000 ms 
of instruction (Figure 7a; 500 ms: M=21.8, SE=2.25, SD=13.9; 1000 ms: M=27.6, SE=3.92, 
SD=24.2). There was also a significant main effect of Trial Type [F(1,9)=70.2 p<.001], as SLRs 
were significantly smaller on Anti-reach trials than on Pro-reach trials (Anti-reach: M=10.2, 
SE=1.19, SD=7.36; Pro-reach: M=39.2, SE=2.85, SD=17.5). There was a significant interaction 
between Instruction Time and Trial Type [F(1,33)=41.1, p<.001], which revealed that SLR 
magnitude was significantly greater with 500 ms of instruction time than with 1000 ms of 
instruction time on Anti-reach trials (500 ms: M=12.0, SE=1.77, SD=7.51; 1000 ms: M=8.34, 
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SE=1.63, SD=6.90; p<.001), but smaller with 500 ms of instruction time than with 1000 ms of 
instruction time on Pro-reach trials (500 ms: M=31.5, SE=2.79, SD=11.8; 1000 ms: M=46.8, 
SE=4.53, SD=19.2; p<.001). This result highlights the relationship between Instruction Time and
the influence of the task instruction on the magnitude of the SLR. Figure 7a shows that when 
participants have more time to consolidate the cue, the SLR can be more significantly dampened 
on Anti-reaches. Surprisingly, there was no significant main effect of Medication State on the 
magnitude of the SLR [F(1,9)=1.33, p=.280]. Mean SLR magnitude was slightly smaller while 
off medication than while on medication, however unlike the effect of Medication State on 
movement-related EMG activity, there was no consistent trend towards decreased activity in the 
OFF condition during the SLR period (OFF: M=23.8, SE=3.14 SD=18.9; ON: M=25.5, SE=3.29, 

























Figure 7 A) Mean (SEM) SLR magnitude on pro- and anti-reaches B) Mean (SEM) SLR magnitude 
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3.2.3 SLR to Movement-related Activity Comparison 
 
The purpose of this analysis was to determine the magnitude of the SLR in each 
condition relative the movement-related activity in the respective condition. There was a 
significant main effect of trial type, as the magnitude of the SLR was a significantly smaller 
proportion of movement-related activity on Anti-reach trials compared to Pro-reach trials (Figure 
7b; Anti-reach: M=14.2%, SE=2.10, SD=12.9; Pro-reach: M=48.8%, SE=3.50, SD=21.7). There 
was no significant main effect of Instruction Time [F(1,9)=3.13, p=.111]. Participants had a 
slightly smaller SLR relative to movement-related EMG activity with only 500 ms of instruction, 
compared to 1000 ms of instruction (500 ms: M=28.6%, SE=3.10, SD=19.0; 1000 ms: M=34.4%, 
SE=4.80, SD=29.6; p<.001). There was a significant interaction between Instruction Time and 
Trial Type, which indicated that the SLR magnitude was a greater proportion of movement-
related EMG activity with 500 ms than with 1000 ms of instruction on Anti-reach trials (500 ms: 
M=17.0%, SE=3.23, SD=13.9; 1000 ms: M=11.4%, SE=2.74, SD=11.6; p<.001), but a smaller 
proportion with 500 ms than with 1000 ms on Pro-reach trials (500 ms: M=40.2%, SE=3.83, 
SD=16.3; 1000 ms: M=57.3%, SE=5.53, SD=23.5; p<.001). These findings highlight the 
surprisingly large magnitude of the SLR in comparison to movement-related activity, particularly 
when participants are instructed to reach towards the target and have more time to process the 
instructional cue. There was no main effect of Medication State on the SLR magnitude expressed 
as a proportion of movement-related activity [F<1]. The mean percentage was consistent in the 
OFF and ON states (OFF: M=31.8%, SE=4.00 SD=2.37; ON: M=31.2%, SE=3, SD=4.10, 
SD=2.61). There were no other significant interactions between predictors (p>.05).  
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3.2.4 SLR Modulation 
 
SLR modulation was quantified with an index that represents the amount that the SLR 
was dampened on Anti-reach trials relative to Pro-reach trials. An index of 1 indicated complete 
suppression of the SLR on Anti-reach trials, and an index of 0 indicated SLRs of equal 
magnitude were generated on Anti- and Pro-reach trials. Higher values indicated greater 
modulatory control of the SLR. In accordance with the SLR magnitude results, there was a 
significant main effect of Instruction Time on SLR modulation [F(1,13)=17.5, p=.001], but not a 
significant main effect of Medication State [F(1,10)=1.78, p=.212].  Participants had a lower 
modulation index with 500 ms of instruction time than with 1000 ms of instruction time (Figure 
7c; 500 ms: M=.471, SE=.050, SD=.220; 1000 ms: M=.732, SE=.039, SD=.170). The mean 
modulation index was slightly higher while off medication relative to on medication (OFF: 
M=.652, SE=.057, SD=.242; ON: M=.556, SE=.050, SD=.225), however this difference was not 
significant. There was not a significant interaction between Medication State and Instruction 
Time (p>.05), indicating that regardless of instruction time, there was no difference between 
SLR modulation in OFF and ON state.  
 
3.2.5 Movement-related Activity 
The effects of Instruction Time, Trial Type, and Medication State on movement-related 
EMG activity were assessed to investigate whether there are differential effects of these variables 
on voluntary muscle recruitment immediately preceding movement onset compared to the effects 
of these variables on the SLR.  There was no main effect of Instruction Time [F<1], and 
participants had very similarly-sized bursts of EMG activity preceding movement with 500 ms of 
instruction and 1000 ms of instruction (Figure 7d; 500 ms: M=82.3, SE=4.95, SD=31.3; 1000 ms: 
M=83.4, SE=5.00, SD=31.6). There was also no significant main effect on Trial Type [F<1], and 
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the magnitude of movement-related EMG activity was similar preceding Anti-reaches and Pro-
reaches (Anti-reach: M=81.5, SE=5.05, SD=31.9; Pro-reach: M=84.3, SE=4.90, SD=31.0). There 
was also no significant main effect of Medication State on the magnitude of EMG activity 
immediately preceding movement onset [F(1,9)=2.54, p=.145], however participants had lower 
movement-related activity in the OFF condition than in the ON condition (OFF: M=76.6, 
SE=3.66, SD=23.1; ON: M=89.1, SE=5.84, SD=37.0). Although not significant, Figure 7d 
illustrates the clear tendency of movement-related EMG activity to be smaller in the OFF 
condition relative to the ON condition, on both Anti- and Pro-reach trials. This consistent trend 
suggests an influence of dopaminergic medication on muscle activity immediately preceding 
movement initiation, which was not observed in the results of SLR magnitude. There were no 
significant interactions between predictor variables (p>.05).  
In summary, Medication State had no influence on the SLR latency, prevalence, or 
magnitude. The unexpected lack of Instruction Time x Trial Type x Medication State interaction 
effect on SLR magnitude indicated that Medication State did not differentially affect SLR 
magnitude in the Anti-reach condition. This translates to no effect of Medication State on the 
modulation of the SLR, which does not support the hypothesis that DA input to the dorsal 
striatum (DS) is critical for the contextual control of the SLR. Instruction Time significantly 
influenced the magnitude and modulation of the SLR, but even with only 500 ms of instruction 
time participants suppressed the SLR on Anti-reach trials to the same degree in the OFF and ON 
conditions. Interestingly, there was consistently stronger EMG activity during the movement-
related burst in the ON condition, suggesting that although the voluntary muscle recruitment was 
affected by DA, the initial stimulus-driven wave of muscle recruitment comes from a separate, 
DA independent system.  
 
3.3 Relationship with Clinical Measures   
 
Although the sample size was small, we conducted exploratory analysis to see if any 
clinical measures were correlated with a number of behavioural and EMG measures. 
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Multiple linear regression models indicated that disease duration, Freezing of Gait (FOG) score, 
and MDS-UPDRS score in the OFF condition did not significantly predict stimulus-locked 
response (SLR) magnitude (F(3,5) =3.18, p=.122, R2=.450), SLR modulation (F(3,5) 
=5.10, p=.060, R2=.606), reaction time (F(3,6) =2.54, p=.152, R2=.340), peak velocity (F(3,6) 
=.036, p=.990, R2=-.474) time to peak velocity (F(3,6) =3.58, p=.086, R2=.463), error rate 
(F(3,6) =3.42, p=.094, R2=.631), or movement-related EMG activity (F(3,5) 
=2.76, p=.152, R2=.397).   
Chapter 4 
4 Discussion  
 
4.1 Summary of Results 
 
To assess the modulation of the stimulus locked-response (SLR) in patients with 
Parkinson’s disease (PD), it was essential that participants understood the task and were able to 
respond appropriately to the contextual cue. At the same time, one of the primary goals of this 
study was to investigate the effect of a shorter instructional time on SLR modulation, following 
the surprising result from previous work in the lab that SLR modulation was unaffected in PD 
patients, with the assumption that a more challenging task might be necessary to precipitate 
group differences. The error rate and reaction time results indicate that participants were able to 
understand the task and performed very well in both the OFF and ON condition. It is evident 
from the error rate and reaction time data that the manipulation of instruction time from 1000 to 
500 ms was successful at making the task more challenging, without preventing the participants 
from performing a reasonable number of correct trials.  
Although not statistically significant, the trends of the medication effect on reach 
kinematics suggest bradykinetic movement in this sample of PD patients. Participants had 
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consistently lower peak velocities, longer times to peak velocity, and consequently longer 
movement durations in the OFF state compared to the ON state. This trend is congruent with the 
assumption that voluntary movement was affected by basal ganglia (BG) dysfunction in these 
patients, such that intact visuomotor responses would indicate a differential effect of the disease 
on these two types of movement. This assumption is also confirmed by the statistically 
significant increase in scores on the Movement Disorders Society Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS) in the OFF condition relative to the ON condition. Together, these 
results also validate the manipulation of dopaminergic medication state. They confirm that the 
ON sessions were conducted at the appropriate time in participants’ daily medication schedule to 
avoid the effects of the medication wearing off during the sessions, and that withholding 
medication for 16-18 hours before the OFF sessions was sufficient to see the expected effect of 
dopamine (DA) deficiency on motor symptoms.  
Despite the successful manipulation of task difficulty by varying the instruction time, and 
the validated manipulation of dopaminergic medication between ON and OFF sessions, there 
was no effect of DA depletion on the SLR. The prevalence, latency, and magnitude of the SLR 
was equivalent in the OFF and ON conditions, supporting the hypothesis that DA pathways in 
the BG are not critical for the generation of fast visuomotor responses. PD patients generated 
SLRs on the vast majority of trial conditions, with 100% of patients expressing SLRs on Pro-
reaches with 1000 ms of instruction time in both the OFF and ON conditions. Additionally, it is 
worth noting that the mean SLR magnitude on Pro-reaches with 1000 ms of instruction time both 
off and on medication was almost 60% of the magnitude of movement-related EMG activity, 
indicating a high degree of output from the fast visuomotor pathway in PD patients, regardless of 
DA deficiency in the BG. Interestingly, while the magnitude of the SLR was nearly identical in 
  
          
   
                                                                                                                                                      51 
   
         




   
 
 
the OFF and ON conditions, the magnitude of movement-related activity was consistently 
smaller in the OFF condition. Collectively with the finding of decreased velocity and 
acceleration in the OFF condition, this further supports the notion of different pathways 
converging on motor neurons, with the fast visuomotor pathway carrying less susceptibility to 
DA than the slower volitional pathway.  
The most surprising result of this study was the lack of an Instruction Time x Trial Type 
x Medication State interaction on SLR magnitude, and consequently the lack of an effect of 
Medication State on SLR modulation. Though the generation of rapid visuomotor responses was 
expected to be intact in PD, it was hypothesized that the dorsal striatum (DS) of the BG plays an 
essential role in suppressing the SLR when the stimulus location is incongruent with the 
movement goal (i.e., Anti-reach trials). However, the null result suggests that this process is not 
affected by DA deficiency. PD patients generated significantly smaller SLRs on Anti-reach trials 
than on Pro-reach trials in all conditions, which is consistent with the effect of Trial Type on the 
SLR reported by studies in younger, healthy participants. Importantly, the modulation index, or 
the ratio of the SLR on Anti-reach to Pro-reach trials, was not significantly different in the OFF 
and ON conditions. Furthermore, the index was slightly higher in the OFF state suggesting that 
the inability to detect a deficit in the OFF state was not simply attributable to a lack of statistical 
power. Despite increased task difficulty on trials with 500 ms of instruction time as seen by the 
significant decrease in the modulation index compared to trials with 1000 ms, there was still no 
benefit of DA medication on SLR modulation.  
 
4.2 The SLR is Intact in PD 
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The finding of a robustly intact stimulus-locked response (SLR), independent of 
dopamine (DA) medication state, is congruent with the current literature reporting a seemingly 
paradoxical, spared fast visuomotor system in patients with Parkinson’s disease (PD). Firstly, 
these results are consistent with recently collected data by our lab (Kozak) in PD patients. Kozak 
found no differences between PD patients and healthy controls in SLR prevalence, latency, or 
magnitude, and no effect of Medication State, suggesting that the visuomotor pathway 
responsible for generating the SLR is not impaired by DA deficiency in the dorsal striatum (DS). 
Further, our results are consistent with the findings of Merritt et al., (2017) that online 
corrections to stimulus-guided reach trajectories can be performed by PD patients with the same 
latency and accuracy as healthy controls. These online corrections are thought to be initiated by 
the same neural circuitry as the SLR, given that SLRs are associated with shorter latency online 
corrections when assessed in the same task (Kozak et al., 2019). Therefore, it was expected that 
the SLR would be similarly spared by PD. 
The high incidence and magnitude of the SLR in PD patients is also consistent with 
results of oculomotor studies. The effect of PD on saccadic eye movements differs between 
externally cued reflexive saccades, and non-cued volitional saccades (i.e. memory guided 
saccades). In the presence of a visual stimulus, PD patients make more short-latency express 
saccades than healthy controls (Briand et al., 1999; Chan et al., 2005; Terao et al., 2011; Lu et 
al., 2019). This result suggests that fast visuomotor responses are not only intact in PD patients 
but may even be upregulated. This is in stark contrast to the significant delay in volitional eye 
movements in the absence of a visual stimulus seen in PD patients. Given that the SLR is also a 
stimulus-driven, short latency response, likely generated by the tecto-reticulospinal tract (Gu et 
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al., 2016; Gu et al., 2018; Kozak et al., 2019; Kozak et al., 2021), it is unsurprising that our 
results correspond with reports of express saccades in PD patients.  
Our SLR results support the current hypothesis that fast visuomotor responses remain 
intact in PD, despite over-inhibition of volitional movement, suggesting a separate motor 
pathway is involved. In PD, GABAergic output from the internal segment of the globus pallidus 
(GPi) and substantia nigra pars reticulata (SNr) to the intermediate layers of the SC is enhanced 
by upregulation of the indirect, and downregulation of the direct pathway of the basal ganglia 
(BG), caused by DA depletion in the DS (See Chapter 1). The resulting over-inhibition of 
downstream motor areas is responsible for the primary motor symptoms of PD: reduced and 
slowed volitional movement. The results of this study exhibit the expected trends of reduced 
reach velocity and acceleration, and increased movement duration in the OFF condition. It was 
expected that reaction times would be prolonged in the OFF condition, however previous studies 
have also shown no effect of DA on reaction times on simple reaching tasks, even when reaction 
times were significantly longer than healthy controls and DA medication improved MDS-
UPDRS scores (Jahanshahi et al., 1992; Michely et al., 2012). Therefore, this task may not have 
been complex enough to see the effect of DA therapy on reaction times, but there may still be an 
apparent deficit when we compare this data to healthy controls.  
Although the exact mechanisms of spared visuomotor responses in PD are unknown, 
inferences can be made from studies of the neural substrates of oculomotor control via 
converging projections to the superior colliculus (SC), which is presumed to be the common 
origin of both saccadic eye movements and the SLR. The fronto-BG-SC pathway is essential for 
both initiating and inhibiting visuomotor commands sent from the SC to the downstream 
reticular formation, and subsequently to motor neurons involved in orienting the eyes, head, and 
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limbs (Figure 8). SC neurons in the caudal and rostral regions initiate and suppress reflexive eye 
movements towards salient stimuli respectively, and the relative activity in each of these regions 
dictate the behavioral outcome (Munoz & Wurtz, 1992). Modulatory projections originating in 
cortical regions including the dorsal lateral prefrontal cortex (dlPFC), frontal eye field (FEF), 
supplementary eye field (SEF), and posterior parietal cortex (PPC) reach SC neurons directly, 
and indirectly via the inhibitory BG (Mountcastle et al., 1975; Lynch et al., 1977; Stanton et al., 
1989; Pare & Wurtz, 1997; Munoz, 2002; Brown et al., 2006; Dash et al., 2020). Generally, the 
intermediate layer of the SC receives predominantly inhibitory input directly from the BG and 
dlPFC, and excitatory input from the FEF, PPC, and cerebellum (Gaymard et al., 2003). The 
dlPFC and FEF also exert inhibitory effects on the SC via projections to the caudate nucleus 
(CN) and subthalamic nucleus (STN) in the BG, which in turn increases GABAergic output of 
the GPi/SNr.  
Motor output from the intermediate and deep layers of the SC is involved in both 
reflexive (stimulus driven) movements, and voluntary (internally driven) movements, and 
distinctions in the way in which these responses are modulated are important for understanding 
the preservation of the SLR in PD. Specifically, the dlPFC, FEF, and SEF are predominantly 
involved in volitional saccades, such as memory-guided or un-cued saccades, whereas the PPC is 
predominantly involved in reflexive, cued saccades (Pierrot‐Deseilligny et al., 1987; Shibutani et 
al., 1984; Pierrot‐Deseilligny et al., 1991; O’Driscoll et al., 1995; Schall et al., 1995; Sweeney et 
al., 1996; Thier & Anderson, 1996; Andersen et al., 1997; Grosbras et al., 1999; Gaymard et al., 
2003; Parton et al., 2007).  Dash and colleagues (2020) reported that inactivation of the FEF 
reduced the peak velocity of express (short-latency, stimulus-driven) saccades, but did not 
abolish them, suggesting that the FEF is involved, but not essential in express visuomotor 
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responses. Terao et al. (2016) assessed internally driven and stimulus driven saccades in patients 
with a variety of cortical lesions and found FEF lesions were associated with prolonged latency 
of internally driven, but not stimulus driven saccades. In contrast, lesions in the PPC were 
associated with prolonged latency of stimulus driven saccades. dlPFC lesions were associated 
with impaired ability to suppress automatic, stimulus-driven saccades when instructed to make a 
voluntary saccade in the opposite direction (anti-saccade), which supports the notion that the 
direct inhibitory projection from the dlPFC to the SC is a critical pathway for the suppression of 
competing reflexive responses in favour of initiating voluntary movement (Guitton et al., 1985; 
Munoz & Everling, 2004; Pierrot-Deseilligny et al., 2004; Hodgson et al., 2007).  
In PD patients, aberrant activity in the BG and dlPFC is associated with deficits in 
executing internally driven actions and suppressing unwanted stimulus driven responses. 
Jahanshahi et al. (2010) reported that internally guided movements were associated with greater 
activation of the dlPFC compared to externally guided movements, and that the dlPFC was 
hypoactive in patients with PD compared to controls. The hypoactivity of the dlPFC was 
correlated with hyperactivation of the GPi, which has inhibitory output to the dlPFC. 
Consequently, the inhibitory projection from the dlPFC to the SC which is activated during 
internally guided movements, in downregulated in PD. The hypoactive dlPFC is hypothesized to 
play a role in the inability of PD patients to suppress reflexive visuomotor responses during 
voluntary movement, as seen on numerous oculomotor tasks (Briand et al., 1999; Hood et al., 
2007; Chan et al., 2005; Cameron et al., 2009). According to Brown et al., the default response 
of SC motor neurons is to orient the head, eyes, and limbs towards salient stimuli according to 
direct visual input to the superficial layer, and sufficient inhibition is required to perform an 
action that is not congruent with stimulus-driven reactions. Therefore, hypoactive dlPFC 
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projections selectively impair volitional movements, leaving visually guided responses, like the 
SLR, intact and possibly upregulated. 
In addition to reduced activity in the dlPFC in PD, Jahanshahi et al. (2010) also reported 
increased cerebellar activation. This was also reported by Yu et al. (2007), who interpreted this 
finding as a compensatory mechanism in response to increased inhibitory output from the BG. 
Interestingly, the BOLD activation of the ipsilateral cerebellum and the contralateral putamen 
were negatively correlated in PD patients performing a thumb pressing task. Additional evidence 
for this hypothesis comes from Wu et al. (2009; 2010), who found that recruitment of the 
cerebello-thalamo-cortical loop was positively correlated with MDS-UPDRS scores, whereas 
recruitment of the striato-thalamo-cortical loop was negatively correlated with MDS-UPDRS 
scores. It is still unclear whether this phenomenon is indeed compensatory, or a pathological 
result of uninhibited cerebellar activity (Wu et al., 2013). Critically for the interpretation of the 
results of this study, the cerebellum has excitatory projections to the SC, and the downstream 
reticular formation (Noda et al., 1990; Stein & Glickstein, 1992; Fuchs et al., 1993; Guillaume & 
Pelisson, 2001; Robinson & Fuchs, 2001; Thier & Mock, 2006; Buzunov et al., 2013). 
Inactivation of the caudal fastigial nucleus (cFN) of the cerebellum in non-human primates 
significantly impairs saccades towards a target (Goffart et al., 2004). Further, gaze shifts evoked 
by stimulation of the deep layers of the SC were slower and smaller when the cFN was 
inactivated. Therefore, although the increased inhibitory output from the BG to the SC 
theoretically inhibits both internally guided and stimulus guided movement, the hypoactivity of 
the dlPFC during volitional movement and the hyperactivity of the cerebellum might make it 
difficult for the volitional motor command to be executed before the reflexive response is 
triggered in the SC, resulting in a response bias towards automatic actions in PD patients. Given 
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the stimulus-driven and automatic nature of the SLR, the results of our study are congruent with 
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4.3 SLR Modulation is Intact in PD Patients, but Sensitive to Instruction Time  
 
In light of the literature discussed above, it was hypothesized that the modulation of the 
stimulus-locked response (SLR) would be impaired in Parkinson’s disease (PD), and that this 
deficit would be remedied by dopamine (DA) medication. However, the results of our study do 
not support this hypothesis and suggest that the system modulating the SLR is independent of 
DA loops in the basal ganglia (BG). This result conflicts with the well-documented deficit in PD 
patients in suppressing automatic responses to external stimuli, in favour of initiating a voluntary 
response that is incongruent with the stimulus. In the PD literature, the anti-saccade task is the 
most analogous behavioural task to the anti/pro-reach task used to study the SLR. PD patients 
show profound deficits in the ability to inhibit a saccade towards a suddenly appearing target 
(Briand et al., 1999; Chan et al., 2005; Terao et al., 2011; Terao et al., 2013; Lu et al., 2019). 
Therefore, the finding that the SLR is significantly dampened on Anti-reach trials compared to 
Pro-reach trials was unexpected. Further, PD patients have a response bias towards automated 
movements. Compared to healthy controls, they have more difficulty switching from an 
automatic motion to a volitional motion but perform better than healthy controls when switching 
from a volitional to an automated motion (Cameron et al., 2010). The literature consistently 
indicates a role of the dorsal striatum (DS) in the modulation of automatic visuomotor responses 
(Praamstra et al., 2001; Obeso et al., 2008; Gauggel et al., 2004; Cools, 2006; Hood et al., 2007; 
Ali et al., 2010; Beste et al., 2010; Liu et al., 2010; Zandbelt et al., 2013), however this was not 
supported by our SLR modulation results. 
This surprising result has two possible explanations. First, the SLR could be modulated 
by a different mechanism than other express oculomotor responses, which are well-known to be 
upregulated and disinhibited in PD patients. The exact neural circuitry of the generation and 
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modulation of the SLR is not as clear as the neural circuitry involved in generating eye 
movements, and so it is possible that the assumed role of the BG-superior colliculus (SC) 
pathway in SLR modulation is incorrect. However, the strong evidence for the role of the SC in 
generating the SLR, and the recruitment of the striatum for response inhibition on a wide range 
of cognitive and motor tasks render this explanation unlikely (Brown & Marsden, 1988; Henik et 
al., 1993; Dujardin et al., 1999; Cools, 2006; Ali et al., 2010; Liu et al., 2010; Zandbelt et al., 
2013; Jahanshahi et al., 2015).  
The alternative, and more likely, explanation is that there is a deficit in the contextual 
control of the SLR in PD patients, especially with shorter instruction times, that is not affected 
by DA medication. The effect of DA medication on deficits on the anti-saccade task in PD 
patients is inconsistent across studies, and deficits are frequently reported in patients both on and 
off their prescribed medication (Briand et al., 1999; Hood et al., 2007; Chan et al., 2005; 
Cameron et al., 2009). Therefore, the lack of a medication effect on the modulation of the SLR 
must be interpreted with caution. Though the SLR modulation index is relatively high with 1000 
ms of instruction (~0.70), indicating an influence of task instruction on the magnitude of 
stimulus-driven muscle recruitment, the index is significantly reduced with only 500 ms of 
instruction time. It could be that the modulation of the fast visuomotor pathway is not abolished 
in PD, but rather requires more time for the contextual information to influence visuomotor 
responses. This is compatible with a large group of experiments involving simple reaction time 
and cued choice reaction time tasks, which showed that PD patients can process, and benefit 
from pre-stimulus cues, but they require longer cues than healthy controls to gain the same 
amount of “benefit” (i.e. the same reduction in reaction time relative to uncued trials) (Talland, 
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1963; Wiesendanger et al., 1969; Girotti et al., 1986; Stelmach et al., 1986; Mayeux et al., 1987; 
Lichter et al., 1988; Reid et al., 1989). 
The results of SLR magnitude show that instruction time has significant effects on both 
Anti- and Pro-reach trials suggesting that the instruction time is used to either prime or suppress 
the SC accordingly. With longer instruction times, the SLR is significantly smaller on Anti-reach 
trials and greater on Pro-reach trials. Collectively with the prolonged reaction time, and higher 
error rates on trials with only 500 ms of instruction time, this supports the hypothesis that the 
bias towards stimulus driven responses in PD might be because of a deficit to initiate the 
voluntary response and suppress the automatic response before the automatic response is 
initiated by excitatory visual input into the SC. Testing this hypothesis will require a control 
group, which will elucidate whether there is a modulation deficit in PD compared to healthy 
controls, or whether SLR modulation is indeed independent from the pathological effects of PD. 
The results of this study so far indicate that the design is well-equipped to make informative 
comparisons of the effect of instruction time on SLR modulation in PD versus HC, given the 
difficulty of trials with only 500 ms of instruction for patients. I predict that the difference in 
modulation between trials with 500 ms and 1000 ms of instruction will be greater in the PD 
group compared to HC.  
 
4.4 Limitations and Future Directions  
 
The greatest limitation of this study was the lack of control data as a consequence of the 
COVID-19 pandemic. This study was initially designed with the intention of comparing 
stimulus-locked response (SLR) modulation in patients with Parkinson’s disease (PD) to healthy 
controls both off and on dopamine (DA) medication, which would allow us to investigate the 
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effect of the pathology of PD without relying on the effects of DA medication. The current data 
allowed us to address two of our three aims which were to 1) investigate the effect of instruction 
time on SLR modulation in PD, 2) investigate the effect of DA medication on SLR modulation 
in PD, and 3) investigate the effect of PD on SLR modulation. Control data are expected to be 
collected in Fall 2021, which will enable us to address the third aim of this study.  
Additionally, the small sample size limited the statistical power of this study. The 
inability to detect statistically significant differences between the OFF and ON conditions for 
any of the variables analyzed limit our ability to make robust conclusions about the effects of DA 
on the SLR. However, the direction of the trends in the data suggest a differential effect of DA 
medication on EMG activity at different times during the motor response. Specifically, though 
the magnitude of EMG activity during the SLR window was nearly identical in the OFF and ON 
conditions, it was consistently smaller in the OFF condition preceding movement onset. This 
result warrants further investigation to decipher the involvement of DA in the initial wave of 
muscle recruitment compared to the volitional movement. It is also possible that the reaching 
motion required in this paradigm is too simple to elicit significant differences between 
medication states, as the effect of DA medication is known to be more prominent on more 
complex motor tasks (Benecke et al., 1987; Hanna-Pladdy & Heilman, 2010). Therefore, the null 
result of the effect of DA on the SLR could be supported by testing the same group of patients on 
a more complex voluntary motor task which produces measurable effects of DA as a comparison 
to the SLR.   
Finally, this paradigm was designed with a moving target in light of the finding from 
Kozak et al., (2020) that a moving target is superior to a stationary target at eliciting robust 
SLRs. However, this creates a confounding effect of reaction time on the distance the participant 
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must reach to hit the target, as the distance of the target from the initial hand position varies with 
the time from target emergence. Although this should not influence the SLR, this has 
implications for measures of reach amplitude, peak velocity, time to peak velocity, and 
movement duration. This confound creates foreseeable problems when this data is compared to 
healthy controls, as PD patients are expected to have significantly longer reach reaction times. 
More recently, Contemori and colleagues (2020) reported that flashed stationary targets can in 
fact elicit stronger magnitude SLRs than moving targets, as long as the target emergence is 
temporally predictable. Future studies of the SLR in PD patients should take this into 
consideration when designing the paradigm, as using a flashed stationary target will standardize 
the movement goal regardless of any changes in reaction time.  
 
4.5 Conclusions  
 
In conclusion, this study provides strong evidence that rapid visuomotor responses 
remain intact in patients with Parkinson’s disease (PD), as demonstrated by the high prevalence 
and magnitude of stimulus-locked responses (SLRs) on the Emerging Target task. The speed of 
reaches and magnitude of movement related EMG activity was slightly lower in the OFF 
condition, consistent with known EMG abnormalities associated with bradykinesia and 
hypokinesia. In contrast, we found no statistically reliable differences in the magnitude of the 
SLR in the OFF and ON conditions, suggesting a differential effect of dopamine (DA) on 
different stages of muscle recruitment. PD patients demonstrated modulation of the fast 
visuomotor pathway by eliciting smaller SLRs on Anti-reach trials, however the modulation 
index was significantly lower with less instruction time preceding target emergence. Though 
there was no effect of DA medication on the modulation index, control data from healthy 
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participants is needed to confirm whether the effect of instruction time on SLR modulation is 
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For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Group:    Time: 
 
 
Health and Demographic Questionnaire 
Please print and fill out this form as accurately as possible and bring it with you to your first 
appointment session. If you are attending your appointment with another participant, please 
ensure you both have your own personal copies filled out. 
 
 
1. Basic Demographic Information 
 
Date of Birth: _____________________________  Age: _______ 
Weight: ________              Height: _______ 
Handedness: _____________ 
First language: __________________ Other languages: ___________________________ 





2. Health-Related Information 
 
A. Smoking History (please circle): Never Smoker  Ex-Smoker Current Smoker 
If current smoker, indicate how many years and how many cig/day: _______________________ 
If ex-smoker, indicate year that you quit; how many years smoking; how many cig/day: 
______________________________________________________________________________ 
 
B. Alcohol History 
Average number of drinks per week: _____________ 
Has there ever been heavy alcohol consumption? (please circle) Yes No 
If yes, when, for how long, and estimate your weekly alcohol consumption during that time: 
______________________________________________________________________________ 
 
C. Other Drug History 
Have you ever taken street drugs or other drugs that were not prescribed by a physician (please 
circle)?  Yes No 
If yes, when, what drugs, how frequently and over what period of time? 
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For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Group:    Time: 
 
______________________________________________________________________________ 
D. Eye Glasses (only if applicable) 
What is the prescription of your eye glasses? ______________ 
Without the aid of glasses are you able to see near objects well (please circle)? Yes No 
Without the aid of glasses are you able to see far objects well (please circle)? Yes No 
 
E. Obsessive-compulsive disorder (OCD; only if applicable) 
What year were you diagnosed with OCD? _________________ 
Are you currently taking medication to treat your OCD? _________________ 
If yes, what medication? _________________ 
 
F. Parkinson’s Disease (PD; only if applicable) 
What year were you diagnosed with Parkinson’s disease? _________________ 
Which side of the body is more affected? _________________ 
 
3. Previous Medical Problems 
Have you had any major health problems or do you have any chronic, ongoing medical 
conditions such as high blood pressure, high cholesterol, diabetes, thyroid problems, multiple 
sclerosis or epilepsy?  Have you had any strokes, heart attacks/ heart surgeries, significant head 
trauma, or cancer?  If you've had cancer, what kind and what treatments did you receive (e.g. 
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For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Group:    Time: 
 
 
4. Family Medical Problems 
Is there anyone in your family with a neurological or serious psychiatric illness such as PD, 
Huntington's, epilepsy, strokes at a young age (< 50 for men and < 60 for women)?  Is there 
anyone who had trouble walking or with balance, needing a wheelchair or a walker at a young 
age?  Any family members with dementia (such as Alzheimer's), schizophrenia, bipolar/manic 
depression, or severe depression or anxiety requiring hospitalization or close follow up by a 
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For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Group:    Time: 
 
5. Current Medication 
Please list any medications you are currently taking, what they are treating for specifically, and 
the prescribed dosage. 
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The research is funded by a Canada Excellence Research Chair to Dr. Adrian Owen, an Academic 
Medical Association of Southwestern Ontario Opportunity Fund and Natural Sciences and 
Engineering Research Council of Canada awarded to Dr. Penny MacDonald. 
 
Purpose 
You are being asked to participate in a research project designed to help us understand more 
about attention, memory, and how people make every day decisions.  The study will help show 
which parts of the brain are involved in these functions.  It will also help us to understand 
whether certain illnesses that affect the brain such as strokes or Parkinson’s disease, or 
obsessive-compulsive disorder change the way people pay attention, remember, and make 
decisions.  Understanding these changes might help us to provide better care for these patients 
ultimately.  We will aim to recruit approximately 200 patients with Parkinson’s disease, 200 
healthy volunteers, matched in age to PD patients, 200 patients with strokes, 200 patients with 
neurological or psychiatric disorders that might implicate the striatum (a brain region of 
interest), and 200 healthy volunteers.  The criteria to participate in this study were previously 
outlined in the recruitment letter that you were given. 
 
Procedures 
If you agree, you will be asked to one or two testing sessions at the Brain and Mind Institute or 
the Robarts Research Institute at the University of Western Ontario.  Each session is expected 
to last approximately 1.5 hours, but may go as long as 3 hours.  The first session will begin with 
a short clinical interview to evaluate your general health.  Your heart rate and blood pressure 
might also be recorded.  A screening neurological examination will be performed.  You will also 
be asked to complete a few standard questionnaires to assess aspects of your mood and 
temperament.  In each session, you will next perform a computerized test that is aimed at 
testing basic aspects of thinking, memory, or problem solving.  Explanations of the paper and 
pencil tests will be provided orally and detailed written instructions will be given prior to the 
computerized test on each day.  You will have the chance to ask questions and will be 
encouraged to do so before beginning the tests.  Practice trials will also be provided so that you 
will be comfortable with the computerized test and so that you understand thoroughly what 
you’re asked to do. 
 
Your permission is also requested for Dr. MacDonald to review any CT or MRI scans of the brain 
that you have previously undergone.  This will help us better understand the results of the 
testing. 
 
Experiments involving functional magnetic resonance imaging 
PENNY A. MACDONALD, MD, PhD, FRCP(C)  
Assistant Professor and Movement Disorder Neurologist  
                                                                         Department of Clinical Neurological Sciences and  
  The Brain and Mind Institute 





Version: 29August/2019  
Consent Form                         initials: _________ 
 
 339 Windermere Road  
London, Ontario, Canada N6A 5A5 
Tel: (519) 685-8500 ext. 33631 • Fax: (519) 663-3753 
 
 
LETTER OF INFORMATION AND CONSENT FORM 
 
In this consent document, “you” always refers to the study participant. If you are a substitute 
decision maker (SDM) (i.e. someone who makes the decision of participation on behalf of a 
participant), please remember that “you” refers to the study patient. If an SDM is needed for 
this study, you will be asked to review and sign this consent form on behalf of the participant. 
 
Study Title 
Distinguishing the roles of ventral and dorsal striatum in cognition 
 
Investigators  
Penny A. MacDonald MD, PhD, FRCP(C) in Neurology Adrian Owen PhD 
Hooman Ganjavi MD, PhD, FRCP(C) in Psychiatry Mel Goodale PhD 
Seyed Mirsattari MD, PhD, FRCP(C) in Neurology Ravi Menon PhD 
Sarah Morrow MD, FRCP(C) in Neurology Stefan Kohler PhD 
Jorge Burneo MD, FRCP(C) in Neurology Paul Gribble PhD 
Mary Jenkins MD, FRCP(C) in Neurology Ingrid Johnsrude PhD 
Elizabeth Finger MD, FRCP(C) in Neurology Ken McRae PhD 
Stephen Pasternak MD, FRCP(C) in Neurology Lisa Saksida PhD 
Alex Khaw MD, FRCP(C) in Neurology Tim Bussey PhD 
Luciano Sposato MD, PhD, FRCP(C) in Neurology Brian Corneil PhD 
Jennifer Mandzia MD, PhD, FRCP(C) in Neurology Robert Bartha PhD 
Vladimir Hachinsky MD, FRCP(C) in Neurology Jessica Grahn PhD 
David Spence MD, FRCP(C) in Neurology Ali Kahn PhD 
Donald Lee MD, FRCP(C) in Radiology Stuart Fogel PhD 
Mark Watling MD, FRCP(C) in Psychiatry Bjorn Hermann PhD 
Sandra Northcott MD, FRCP(C) in Psychiatry Lorina Naci PhD 
Ken Seergobin MSc Kathryne Van Hedger PhD 
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During testing, you might perform tests on a computer that are aimed at testing basic aspects 
of thinking, memory, or problem solving while you are in a magnetic resonance imaging (MRI) 
machine.  With MRI, we are able to measure blood flow non-invasively in various parts of your 
brain as a marker of brain activity while you perform specific thinking functions.  We will also 
collect images of your brain in the MRI to measure different brain structures. 
 
Patients with Parkinson’s disease 
If you are a patient with Parkinson’s disease, you will be tested twice, once while you are taking 
your Parkinson’s medication and once after you have abstained from taking your Parkinson’s 
medication for at least 12 hours on two separate days.   
 
Healthy control participants or patients with neurological (e.g. stroke, epilepsy, multiple 
sclerosis, multiple systems atrophy, progressive supranuclear palsy, cortico-basal-ganglionic 
degeneration, Lewy body dementia, ataxia, Huntington’s disease, Alzheimer’s disease), as well 
as sleep disorders (e.g. rapid eye movement sleep behavioural disorder or RBD, restless leg disorder and, 
obstructive sleep apnea), or psychiatric disorder (e.g. obsessive-compulsive disorder) other than 
Parkinson’s disease 
If you are a non-patient volunteer or a patient with a neurological or psychiatric disorder other 
than Parkinson’s disease, you might perform the tasks once or twice.  In all testing sessions, you 
will take all of your regularly prescribed medications.  In some studies, you might also take 
dopaminergic therapy or a placebo (i.e., cornstarch) in one session or across two sessions. 
 
Patients with addiction (e.g. alcohol, opioids, marijuana) 
 You will be asked to abstain from all illicit substances as well as alcohol for a minimum of 48 
hours prior to testing.  Upon arrival on your testing date, you will complete an Orawell Oral 
Fluid (Saliva) Drug Test and an Alco-Screen Oral Fluid (Saliva) Alcohol Test to confirm 
compliance with these instructions.  In all testing sessions, you will take all of your regularly 
prescribed medications.  In some studies, you might also take dopaminergic therapy or a 
placebo (i.e., cornstarch) in one session or across two sessions. 
 
Healthy control participants studied while taking dopaminergic therapy 
For non-patient volunteers, in some experiments you will perform tasks once while taking a 
dose of Levocarb or Pramipexole, common medications that are used to treat Parkinson’s 
disease, and once while taking an inactive or placebo substance (i.e., cornstarch).  The order in 
which you receive these substances will be randomly determined across participants.  You will 
not be informed of the substance that you are given in either testing session and the 
experimenter will also be blind to which substance you are given on a particular day.  This is 
done to reduce any effects of expectation that might be induced by knowing that you are 
receiving active treatment.  Levocarb contains 100 mg of levodopa (L-3,4-
dihydroxyphenylalanine) and 25 mg of carbidopa.  Levodopa is transformed in the brain into 
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dopamine whereas pramipexole mimics dopamine.  Dopamine is a neurotransmitter produced 
naturally in the brain that is involved in regulating movement and some aspects of thinking and 
memory.  Carbidopa is a substance that does not cross into the brain but is given to stop the 
levodopa from being converted to dopamine before it reaches the brain.  Carbidopa reduces 
side effects that can occur due to dopamine being produced in the body rather than in the 
brain, such as nausea or lowering of blood pressure. 
 
Experiments involving propranolol or atenolol 
You might be asked to perform some tasks once while taking a dose of propranolol or atenolol, 
and once while taking an inactive or placebo substance (i.e., cornstarch).  The order in which 
you receive these substances will be randomly determined across participants.  You will not be 
informed of the substance that you are given in either testing session and the experimenter will 
also be blind to which substance you are given on a particular day.  This is done to reduce any 
effects of expectation that might be induced by knowing that you are receiving active 
treatment.  Propranolol and atenolol are beta blockers.  Beta blockers compete with the same 
receptors as adrenaline, slowing the sympathetic nervous system to lower heart rate and blood 
pressure. 
 
Experiments involving polysomnographic sleep recordings 
You might be asked to undergo polysomnographic sleep recordings during either a 3-h daytime 
nap or 8-h overnight session.  Polysomnography (PSG) is a non-invasive technique that uses 
surface electrodes applied to the scalp and face to measure brain activity during different 
sleep-wake cycles. 
 
Experiments involving robotic arm manipulation 
We will ask you to perform a motor learning task. This will take approximately 40 minutes. You 
will be asked to grasp the handle of one or two robot arms, and point to visual targets displayed 
on a virtual-reality display. You will be asked to point to targets one after another. Depending 
on the phase of the experiment, the robot may be programmed to apply small forces (a few 
grams) to your hand during movement. The robot will measure the movement of the handle 
(e.g., when movement starts, how fast it is, how curved the trajectory of movement is as you 
move to the targets) as an index of motor learning. Throughout the experiment, your muscle 
activity will be measured with surface electromyography (EMG) by small, non-invasive 
electrodes placed on top of the skin with adhesive tape. These electrodes will be placed on the 
upper chest, just below the collarbone. If you have chest hair, the areas where surface 
recording will take place might need to be shaved in order to collect good quality data. You are 
welcome to remove it yourself before arriving to the study, or we can provide razors and 
shaving cream before we attach the electrodes.  
 
Experiments involving electroencephalography 
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You might be asked to undergo electroencephalography (EEG) recordings during either the 
experimental session.  EEG is a non-invasive technique that uses surface electrodes applied to 
the scalp and face to measure brain activity during rest or during performance of various 
cognitive tasks. 
 
Experiments involving audiometric assessment 
You may be asked to listen to sounds through headphones and report when you detect the 
sound and when you can no longer hear the sound. This part is expected to take no longer than 
12 minutes.  
 
Experiments involving beat/rhythm discrimination 
You may be asked to complete auditory tasks involving discrimination of auditory sequences, 
and/or tapping during or after listening to auditory sequences. For these tasks, auditory 
sequences will be presented via headphones at a comfortable intensity level. Tapping will be 
performed on a computer keyboard or external device (e.g., a drum pad) capable of recording 
tapping information. 
 
Experiments involving affective processing 
You might be asked to view pictures and/or sounds that portray either neural content (e.g., 
chairs, glasses) or negatively valenced content, some of which is graphic or disturbing in nature 
(e.g., guns, threat/attack, body mutilation), or a series of faces.  Your psychophysiological 
responses to these stimuli will be monitored at all times during the task using 
electromyography (EMG), galvanic skin response (GSR), electrocardiography (ECG), heart rate, 
blood pressure, and respiration. 
 
Experiments involving virtual reality 
You might be asked to interact in real-world situations using a virtual reality head set.  During 
the test, your movements will be tracked using cameras.  The virtual reality head set creates a 
virtual environment that you can see and interact with. 
 
Experiments involving driving simulation 
You may be asked to perform driving tasks using a driving simulator.  During the test you will be 
sitting in a cockpit designed to replicate a driver’s seat and surrounded by large screens.  Tests 
will involve performing driving tasks (i.e. navigation, turning, etc…). 
 
Experiments involving social processing 
You might be asked to view a series of faces and make judgments about them (e.g., emotion, 
age), and/or listen to a variety of jokes while evaluating how funny they were. Throughout 
these activities, your facial expression activity will be continuously recorded with 
electromyography (EMG).  
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Your participation in this study is of no direct benefit to you. 
 
Risks 
If you require treatment for any injuries or illness directly related to procedures implemented 
during the study, or if you suffer side effects while on study medication, you should contact 
your study doctor as soon as possible.  The necessary medical care will be provided to you at no 
additional cost to you.  You do not waive any legal rights by signing the consent form. 
 
Participants performing computerized tasks 
There are no known physical risks associated with performing computerized tasks. You may find 
some of the tasks dull or tiring.   
 
Experiments involving functional magnetic resonance imaging 
The Food & Drug Administration (USA) has indicated that for clinical diagnosis an ‘insignificant’ 
risk is associated with human MRI exposure at the intensities used in this project.  Current 
Canadian guidelines follow the USA guidelines.  Although very rare, injury and deaths have 
occurred in MRI units from unsecured metal objects being drawn at high speeds into the 
magnet or from internal body metal fragments of which the subject was unaware or had not 
informed MRI staff.  To minimize this latter possibility it is essential that you complete a 
screening questionnaire.  Other remote but potential risks involve tissue burns and temporary 
hearing loss from the loud noise inside the magnet.  The latter can be avoided with ear 
headphone protection that also allows continuous communication between the subject and  
staff during the study.   
 
This MRI machine uses a strong magnet and radio waves to make images of the body interior.  
You will be asked to lie on a long narrow couch for an hour while the machine gathers data.  
During this time you will be exposed to magnetic fields and radio waves.  You will not feel 
either.  You will, however, hear repetitive tapping noises that arise from the magnets that 
surround you.  You will be provided with earplugs or headphones that you will be required to 
wear to minimize the sound and protect your hearing.  The space within the large magnet in 
which you lie is somewhat confined, although we have taken many steps to relieve the 
“claustrophobic" feeling.  There are no known significant risks with this procedure at this time 
because the radio waves and magnetic fields, at the strengths used, are thought to be without 
harm.  The exception is if you have a cardiac pacemaker, or a metallic clip in your body (e.g., 
an aneurysm clip in your brain), have severe heart disease, body piercings, tattoos containing 
metallic ink or slow release pharmaceutical skin patches. 
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There is a possibility that you will experience a localized twitching sensation due to the 
magnetic field changes during the scan.  This is not unexpected and should not be painful.  
However, you can stop the exam at anytime.  The magnetism and radio waves do not cause 
harmful effects at the levels used in the MRI machine.  However, because the MR scanner uses 
a very strong magnet that will attract metal, all metallic objects must be removed from your 
person before you approach the scanner.  In addition, watches and credit cards should also be 
removed as these could be damaged (these items will be watched for you). 
 
For experiments involving electrophysiological recording (e.g, EMG) inside of the MRI: while 
rare, incidents of tissue burning have been reported due to the recording electrodes and cables 
heating up inside of the magnet. However, this risk is largely eliminated when proper 
equipment and procedures are used. The surface electrodes and cables we use have been 
specially designed for use within the MRI and there have been no known burn incidents 
reported with this particular equipment. Furthermore, you will also be separated from the 
cables by an insulating barrier, and your skin will be prepared according to recommended 
safety procedures prior to electrode placement. 
 
Patients with Parkinson’s disease 
For Parkinson’s patients who are tested off of their Parkinson’s medications, you likely will 
experience an increase in your Parkinson’s symptoms.  If you do not return to your usual level 
of function after resuming your medication at the conclusion of the testing session, you are 
invited to contact Dr. MacDonald to discuss your concerns as well as medication strategies for 
getting back to your usual self. 
 
Participants taking dopaminergic therapy 
If you are a non-patient volunteer taking levodopa or pramipexole, there is a potential risk of 
developing side effects following drug administration.  More serious side effects reported are 
based on chronic use of these medications in patients, and are not expected to develop in this 
study given the single, low-dose of drug administered.  Less serious side effects are largely 
peripheral effects (e.g., nausea) and should be minimized through co-administration of 
Carbidopa.  Any side effects that do occur are temporary and should quickly subside.  In the 
unlikely situation that your symptoms persist, you are invited to contact the experimenter to 
discuss your concerns. 
 
Less serious side effects include: mild nausea, dry mouth, loss of appetite; heartburn, diarrhea, 
constipation; headache, dizziness, drowsiness, blurred vision; sneezing, stuffy nose, cough, 
other cold symptoms; sleep problems (insomnia), strange dreams, muscle pain, 
numbness/tingly feelings, skin rash/itching.  More serious side effects include: severe allergic 
reactions; restless muscle movements in your eyes, tongue, jaw, or neck; worsening of tremors 
(uncontrolled shaking); high fever, stiff muscles, sweating, fast or uneven heartbeats, difficulty 
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breathing, feeling like you might pass out; seizure (convulsions); painful or difficult urination; 
severe nausea, vomiting, or diarrhea; uneven heart rate or fluttering in your chest; confusion, 
hallucinations, anxiety, agitation, depressed mood, thoughts of suicide or hurting yourself; 
unusual or intense urges (e.g., gambling, sexual urges); chest pain or heavy feeling, pain 
spreading to the arm or shoulder. 
 
Experiments involving propranolol 
You should not take propranolol if you have asthma. If you are a volunteer taking propranolol, 
there is a potential risk of developing side effects following drug administration.  More serious 
side effects reported are based on chronic use of these medications in patients, and are not 
expected to develop in this study given the single, low-dose of drug administered.  Any side 
effects that do occur are temporary and should quickly subside.  In the unlikely situation that 
your symptoms persist, you are invited to contact the experimenter to discuss your concerns. 
 
Less serious side effects include: fatigue; nausea, vomiting, diarrhea, constipation, stomach 
cramps; decreased sex drive, impotence, of difficulty having an orgasm; trouble concentrating, 
sleep problems (insomnia). More serious side effects include: severe allergic reactions; fast, 
slow, or uneven heartbeats; feeling light-headed or fainting; feeling short of breath even with 
mild exertion; dilated neck veins, swelling of ankles or feet; nausea, upper stomach pain, 
itching, loss of appetite, dark urine, clay-coloured stools, jaundice (yellowing of skin or eyes); 
cool pale skin; cold feeling in hands or feet; depression, confusion, hallucinations, slurred 
speech, headache; seizures; severe skin reaction (blistering or peeling skin) 
 
Experiments involving polysomnographic sleep recording and electroencephalography 
The only potential risk is for individuals with extremely sensitive skin. These individuals may 
have a slight skin irritation where the skin has been gently exfoliated during electrode 
application. When we apply the electrodes to the surface of the skin, we use a gentle, 
hypoallergenic medical-grade exfoliant, called NuPrep, to clean the skin where the electrodes 
will be placed. Any mild irritation to the skin normally lasts less than a few hours.  
 
Experiments involving robotic arm manipulation 
The principal potential risk is injury caused by the robotic arm. However, injury is very unlikely 
and we have implemented a range of safety precautions that are widely used for the 
prevention of injury in studies of human motor control involving robots. A number of safety 
precautions have been implemented with respect to the robot linkage. In addition to 
minimizing the applied force, we test for forces at the endpoint. If forces exceed 10 N all forces 
are immediately set to zero. Additional vendor supplied algorithms limit the workspace over 
which forces may be applied. Moreover, all experimental protocols were tested in full prior to 
the experiment. Both you and the experimenter have a switch that instantaneously deactivates 
the robot. In studies over the past 20 years using this setup at both Western and McGill we 
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have not had a single injury or adverse event. The KINARM End-Point Lab is frequently used in 
clinical populations with movement related disorders, and is marketed as an assessment tool in 
these populations. 
 
Experiments involving affective processing 
There is the possibility of emotional and/or mental distress resulting from viewing images with 
extremely graphic, violent, frightening, disturbing, and/or emotionally distressing content and 
listening to sounds that portray equally upsetting or distressing emotional content.  There is 
also a small possibility that some of the recording electrodes may produce mild skin irritation. 
 
Experiments involving virtual reality 
Virtual reality can be disorienting and cause dizziness.  The only potential risk is for individuals 
to develop nausea and vomiting during the task.  Before any testing begins, you will undergo a 
period of acclimatization involving slow movements and interactions in the virtual environment 
to ensure you are comfortable with performing the task.   
 
Experiments involving driving simulation 
Much like virtual reality, the driving simulator can also be disorienting that may lead to nausea 
and vomiting.  Before any testing begins, you will undergo a period of acclimatization involving 
slow movements and interactions in the virtual environment to ensure you are comfortable 
with performing the task.     
 
Confidentiality 
The investigators will maintain all information collected in this study strictly confidential, shared 
only with individuals directly involved in this study, except as may be required by court order or by 
law.  To further ensure your confidentiality, information collected from you will be devoid of any 
unique personal identifier and will be filed under an anonymous subject number.  If any 
publication or presentation results from this research, you will not be referred to by name and no 
potentially identifying information will be released.  The information collected in the course of this 
study is kept on file in a secure location for no less than 25 years.  If you decide you do not want 
this information to be kept on file, simply advise the research team of your wishes, and your 
record will be destroyed.    
 
Your contact and demographic information collected for this study, will be stored in a secure, 
password-protected database held at Western University. Only the researchers of this study and 
the BrainsCAN coordinator, who administers the database system, will have access to your 
identifiable information (e.g. name, date of birth, diagnoses, etc.). The BrainsCAN coordinator will 
not need to review any of your information unless you have consented to be a part of the 
OurBrainsCAN registry. If you agree to be a part of the OurBrainsCAN registry and have indicated 
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that the researchers of this study can enter your identifiable information, they will include the 
contact and demographic information collected for this study. 
 
If you would like to be contacted about future research studies for which you (or your child) may 
be eligible, you can choose to have your identifiable information entered into “OurBrainsCAN: 
University of Western Ontario’s Cognitive Neuroscience Research Registry” by the researchers of 
this study OR alternatively you can be given the web address of OurBrainsCAN where you are able 
to enter your (or your child’s) information. This is a secure database of potential participants for 
research at Western University, which aims to enrol 50,000 volunteers over a period of 5 years. 
The information in this database will be stored indefinitely. The records are used only for the 
purpose of recruiting research participants and will not be released to any third party. When you 
are invited to participate future research studies, you will be given a full description of what your 
involvement would entail. You are, of course, free to turn down any invitation. If, at any time, you 
decide that you do not want your (your child’s) contact information to be a part of this database, 
please contact ourbrains@uwo.ca to remove your information. 
 
Consent to Use and Disclose Information for Research Subjects 
Representatives of the University of Western Ontario Health Sciences Research Ethics Board 
might be granted direct access to your medical records.  A representative of the University of 
Western Ontario Health Sciences Research Ethics Board might contact you or might require 
access to your study-related records to monitor the conduct of the research. Similarly, as this 
study is affiliated with Lawson Research, Lawson’s quality assurance and education may access 
the study data for quality assurance purposes. By signing the consent, you also permit the 




The tests you undergo in this study are not intended to diagnose or monitor any medical 
conditions you may have.  Nevertheless, if information that might be relevant to your care is 




You will receive $20-50 depending on the length (1.5hrs vs. 3hrs) and type (behavioural only vs. 
behavioural with an MRI component) of study in which you are taking part.  This is to 
compensate you for the time and inconvenience associated with your participation. You will 
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Voluntary Participation/Withdrawal from the Study 
Your participation in this research is completely voluntary.  You may refuse to continue 
performing the tasks in this study at any time without any consequences.  You may refuse to 
participate, refuse to answer any questions or withdraw from the study at any time with no 
effect on your future care.  You do not waive any of your legal rights by signing the consent 
form.  If the research investigators find it necessary, and/or in your best interest, you will be 
asked to withdraw from the study.  In the event that you withdraw from the study for any 
reason, you will receive compensation for the sessions that you attended, even if you did not 
complete the entire session.  Your cost of parking will also be reimbursed.  
 
Contact Information 
If you have any questions or concerns regarding the study, you may contact the principle 
investigator.  If you wish to speak to a neutral individual who is not involved in the study at all 
and who will answer any questions about your rights as a research participant or about the 
conduct of the study, you may contact a Patient Relations Specialist from London Health 
Sciences Centre at 519-685-8500 ext. 52036.  
 
Results 
If you’re interested in obtaining the results of the study, we will gladly provide you with a 
summary of our findings once the research is complete.  Please let the investigator know if you 
would like a summary of the results mailed or emailed to you. 
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Consent Form 
Distinguishing the roles of ventral and dorsal striatum in cognition  
Principle Investigator:  Penny A. MacDonald, MD, PhD 
I (_________________________) have read the Letter of Information and Consent form and 
have had the nature of the study explained to me and I agree to participate. All questions have 
been answered to my satisfaction.  I have been provided a copy of the Recruitment/Information 
Letters and the Consent form.  I freely and voluntarily consent to participate in this study. 
 
_______________________________  ___________________ 
Signature of participant          Date 
 
Your signature on this form indicates that you are acting as a substitute decision maker(s) for 
the participant and the study has been explained to you and all your questions have been 
answered to your satisfaction.  You agree to allow the person you represent to take part in the 
study.  You know that the person you represent can leave the study any time. 
 
_______________________________ ___________________         ___________________ 
Signature of substitute decision maker        Relationship to Participant                       Date 
(if applicable)  
 
_______________________________  ___________________ 
Signature of investigator                         Date 
 
I have discussed this clinical research study with the participant using a language that is 
understandable and appropriate.  I believe that I have fully informed this participant of the purpose, 
duration etc. of this research study and its possible benefits and risks and I believe the participant 
understood this explanation. 
 
_______________________________________         ________________________ 





          
   
                                                                                                                                                      104 
   
         










Consent Form                           initials: _________ 
 
  339 Windermere Road  
London, Ontario, Canada N6A 5A5 
Tel: (519) 685-8500 ext. 33631 • Fax: (519) 663-3753 
Optional Consent to be Added to OurBrainsCAN Recruitment Database 
 
I consent to being added to the OurBrainsCAN: University of Western Ontario’s Cognitive 
Neuroscience Research Registry to be contacted about future research studies for which I (or 




________  Yes, I already signed-up. 
 
________  Yes, the researcher can enter my information into the database on my behalf. 
 




Participant’s Name (Please print): ____________________________________ 
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Appendix D: Epworth Sleepiness Scale  
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Patton, Stanford, Barratt (1995), J Clin Psy, vol. 51, pp. 768-774 
For administrator’s use only  Date (dd/mm/yy): 
Subject #:   Session #: 
Score:     Medication:   Time: 
Sub-scores: A:       CI:       M:       P:       SC:       CC:  
 
Barratt Impulsiveness Scale (BIS-11) 
 
Directions:  People differ in the ways they act and think in different situations.  This is a test to 
measure some of the ways in which you act and think.  Read each statement and put an X on 
the appropriate circle on the right side of this page.  Do not spend too much time on any 
statement.  Answer quickly and honestly.  
 
          Rarely/Never                  Occasionally                  Often                  Almost Always/Always 
1. I plan tasks carefully.  
2. I do things without thinking.  
3. I make-up my mind quickly.  
4. I am happy-go-lucky.  
5. I don’t “pay attention.”  
6. I have “racing” thoughts.  
7. I plan trips well ahead of time.  
8. I am self-controlled.  
9. I concentrate easily.  
10. I save regularly.  
11. I “squirm” at plays or lectures.  
12. I am a careful thinker.  
13. I plan for job security.  
14. I say things without thinking.  
15. I like to think about complex problems.  
16. I change jobs.  
17. I act “on impulse.”  
18. I get easily bored when solving thought problems.  
19. I act on the spur of the moment.  
20. I am a steady thinker.  
21. I change residences.  
22. I buy things on impulse.  
23. I can only think about one thing at a time.  
24. I change hobbies.  
25. I spend or charge more than I earn.  
26. I often have extraneous thoughts when thinking.  
27. I am more interested in the present than the future.  
28. I am restless at the theatre or lectures.  
29. I like puzzles.  
30. I am future oriented.  
 
 1  2  3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  
3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  
3  4 
 1  2  
3  4 
 1  2  3  4 
 1  2  3  4 
 1  2  
3  4 
 1  2  
3  4 
 1  2  
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 1  2  3  4 
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 1  2  3  
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 1  2  3  4 
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 1  2  3  4 
 1  2  
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 4 
 1  2  3  4 
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3  4 
 1  2  
3  4 
 1  2  3  4 
Appendix E: Barratt Impulsiveness Scale 
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Oxford Happiness Questionnaire 
The Oxford Happiness Questionnaire was developed by psychologists Michael Argyle and Peter Hills at 
Oxford University.   
Instructions 
Below are a number of statements about happiness. Please indicate how much you agree or disagree 
with each by entering a number in the blank after each statement, according to the following scale: 
1 = strongly disagree 
2 = moderately disagree 
3 = slightly disagree 
4 = slightly agree 
5 = moderately agree 
6 = strongly agree 
Please read the statements carefully, some of the questions are phrased positively and others 
negatively. Don’t take too long over individual questions; there are no “right” or “wrong” answers (and 
no trick questions). The first answer that comes into your head is probably the right one for you. If you 
find some of the questions difficult, please give the answer that is true for you in general or for most of 
the time. 
The Questionnaire 
1. I don’t feel particularly pleased with the way I am. ( R) ______ 
2. I am intensely interested in other people. _____ 
3. I feel that life is very rewarding. _____ 
4. I have very warm feelings towards almost everyone. _____ 
5. I rarely wake up feeling rested. (R) _____ 
6. I am not particularly optimistic about the future. (R) _____ 
7. I find most things amusing. _____ 
8. I am always committed and involved. _____ 
9. Life is good. _____ 
10. I do not think that the world is a good place. (R) _____ 
11. I laugh a lot. _____ 
12. I am well satisfied about everything in my life. _____ 
13. I don’t think I look attractive. (R) _____ 
14. There is a gap between what I would like to do and what I have done. (R) _____ 







Appendix F: Oxford Happiness Questionnaire  
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Version 1.0 (7/01/09) 
Copyright © University  of Pennsylvania 2009 
 
1
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale 
(QUIP-RS) 
 
Reported by:  _____ Patient  _____ Informant  _____ Patient and Informant   
Patient / Subject: __________________________________________ 
Date:   __________________________________________ 
     
1. How much do you think about the following behaviors (such as having trouble keeping thoughts out of your mind or 
feeling guilty)? 
Gambling?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Sex?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Buying?   ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Eating?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Performing tasks or hobbies? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Repeating simple activities? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very  often(4) 
Taking your PD medications? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
 
2. Do you have urges or desires for the following behaviors that you feel are excessive or cause you distress (including 
becoming restless or irritable when unable to participate in them)?   
Gambling?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Sex?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Buying?   ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Eating?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Performing tasks or hobbies? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Repeating simple activities? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very  often(4) 
Taking your PD medications? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
 
3. Do you have difficulty controlling the following behaviors (such as increasing them over time, or having trouble cutting 
down or stopping them)?  
Gambling?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Sex?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Buying?   ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Eating?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Performing tasks or hobbies? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Repeating simple activities? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very  often(4) 
Taking your PD medications? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
  
4. Do you engage in activities specifically to con tinue the following behaviors (such as hiding what you are doing, lying, 
hoarding things, borrowing from others, accumulating debt, stealing, or being involved in illegal acts)?   
Gambling?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Sex?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Buying?   ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Eating?    ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Performing tasks or hobbies? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
Repeating simple activities? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very  often(4) 
Taking your PD medications? ___Never(0)   ___Rarely(1)   ___Sometimes(2)   ___Often(3)   ___Very often(4) 
 
 
Appendix G: Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson’s Disease – Rating Scale 
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Version 1.0 (7/01/09) 
Copyright © University  of Pennsylvania 2009 
 
2
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale 
(QUIP-RS) 
 
Subject:  __________________________________________ 





A.  Gambling    ______ (0-16) 
B.  Sex     ______ (0-16) 
C.  Buying     ______ (0-16) 
D.  Eating    ______ (0-16)  
E.  Hobbyism-Punding  ______ (0-32)  
F.  PD Medication Use  ______ (0-16) 
 
 
Total ICD Score (A-D)  ______ (0-64) 
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Appendix H: Verbal and Category Fluency 
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									Subject	#:	 	 	 Session	#:	
Total:					BS:					D:					ES:					TAS:	 									Medication:	 	 	 Time:	
	
1. A. I like “wild” uninhibited parties 
 B. I prefer quiet parties with good conversation 
   2. A. There are some movies I enjoy seeing a 
second or even a third time 
 B. I can’t stand watching a movie that I’ve seen 
before 
   3. A. I often wish I could be a mountain climber 
 B. I can’t understand people who risk their necks 
climbing mountains 
   4. A. I dislike all body odors 
 B. I like some for the earthly body smells  
   5. A. I get bored seeing the same old faces 
 B. I like to comfortable familiarity of everyday 
friends 
   6. A. I like to explore a strange city or section of 
town by myself, even if it means getting lost 
 B. I prefer a guide when I am in a place I don’t 
know well 
   7. A. I dislike people who do or say things just to 
shock or upset others 
 B. When you can predict almost everything a 
person will do and say he or she must be a 
bore 
   8. A. I usually don’t enjoy a movie or play where I 
can predict what will happen in advance 
 B. I don’t mind watching a movie or a play where 
I can predict what will happen in advance 
   9. A. I have tried marijuana or would like to 
 B. I would never smoke marijuana 
 
 
   
10. A. I would not like to try any drug which 
might produce strange and dangerous 
effects on me 
 B. I would like to try some of the new drugs 
that produce hallucinations 
   11. A. A sensible person avoids activities that are 
dangerous 
 B. I sometimes like to do things that are a 
little frightening 
   12. A. I dislike “swingers” (people who are 
uninhibited and free about sex) 
 B. I enjoy the company of real “swingers” 
   13. A. I find that stimulants make me 
uncomfortable 
 B. I often like to get high (drinking liquor or 
smoking marijuana) 
   14. A. I like to try new foods that I have never 
tasted before 
 B. I order the dishes with which I am familiar, 
so as to avoid disappointment and 
unpleasantness 
   15. A. I enjoy looking at home movies or travel 
slides 
 B. Looking at someone’s home movies or 
travel slides bores me tremendously 
   16. A. I would like to take up the sport of water 
skiing 
 B. I would not like to take up water skiing 
   17. A. I would like to try surf boarding 
 B. I would not like to try surf boarding 
 
 
   
Appendix I: Sensation Seeking Scale 
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18. A. I would like to take off on a trip with no 
preplanned or definite routes, or timetable 
 B. When I go on a trip I like to plan my route 
and timetable fairly carefully 
   19. A. I prefer the “down to earth” kinds of people 
as friends 
 B. I would like to make friends in some of the 
“far out” groups like artists or “punks” 
   20. A. I would not like to learn to fly an airplane 
 B. I would like to learn to fly an airplane 
   21. A. I prefer the surface of the water to the 
depths 
 B. I would like to go scuba diving 
   22. A. I would like to meet some persons who are 
homosexual (men or women) 
 B. I stay away from anyone I suspect of being 
“gay or lesbian” 
   23. A. I would like to try parachute jumping 
 B. I would never want to try jumping out of a 
plane with or without a parachute 
   24. A. I prefer friends who are excitingly 
unpredictable 
 B. I prefer friends who are reliable and 
predictable 
   25. A. I am not interested in experience for its 
own sake 
 B. I like to have new and exciting experiences 
and sensations even if they are a little 
frightening, unconventional, or illegal 
   26. A. The essence of good art is in its clarity, 
symmetry of form and harmony of colors 
 B. I often find beauty in the “clashing” colors 
and irregular forms of modern paintings 
   27. A. I enjoy spending time in the familiar 
surroundings of home 
 B. I get very restless if I have to stay around 
home for any length of time 
   28. A. I like to dive off the high board 
 B. I don’t like the feeling I get standing on the 
high board (or I  don’t go near it at all) 
   29. A. I like to date members of the opposite sex 
who are physically exciting 
 B. I like to date members of the opposite sex 
who share my values 
 
   
30. A. Heavy drinking usually ruins a party 
because some people get loud and 
boisterous 
 B. Keeping the drinks full is the key to a good 
party 
   31. A. The worst social sin is to be rude 
 B. The worst social sin is to be a bore 
   32. A. A person should have considerable sexual 
experience before marriage 
 B. It’s better if two married persons begin 
their sexual experience with each other 
   33. A. Even if I had the money I would not care to 
associate with flight rich persons like those 
in the “jet set” 
 B. I could conceive of myself seeking 
pleasures around the world with the “jet 
set” 
   34. A. I like people who are sharp and witty even 
if they do sometimes insult others 
 B. I dislike people who have their fun at the 
expense of hurting the feelings of others 
   35. A. There is altogether too much portrayal of 
sex in movies 
 B. I enjoy watching many of the “sexy” scenes 
in movies 
   36. A. I feel best after taking a couple of drinks 
 B. Something is wrong with people who need 
liquor to feel good 
   37. A. People should dress according to some 
standard of taste, neatness, and style 
 B. People should dress in individual ways even 
if the effects are sometimes strange 
   38. A. Sailing long distances in small sailing crafts 
is foolhardy 
 B. I would like to sail a long distance in a 
small but seaworthy sailing craft 
   39. A. I have no patience with dull or boring 
persons 
 B. I find something interesting in almost every 
person I talk to 
   40. A. Skiing down a high mountain slope is a 
good way to end up on crutches 
 B. I think I would enjoy the sensations of 
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New Freezing of Gait Questionnaire 
Part I – Distinction Freezer – non-Freezer, over the past month 
1. Did you experience “freezing episodes” over the past month?  
Without video 
Freezing is the feeling that your feet are transiently glued to the floor while trying to initiate 
walking, making a turn or when walking through narrow spaces or in crowded places? 
Sometimes it can be accompanied with trembling of the legs and small shuffling steps.  
 
Additional instructions with video 
We will watch a short video together to see the many ways in which freezing can occur. Also, look carefully for how long these episodes 
last, as you can expect some questions on this later. (tester points out the clock on video clip) 
0. I have not experienced such a feeling or episode over the past month 
1. I have experienced such a feeling or episode over the past month 
If the answer is 1 (patient is a freezer) complete part II and III. The sum of part II and III 
is the final NFOG score. 
Part II – Freezing severity 
2.     How frequently do you experience freezing episodes? 
0. Less than once a week 
1. Not often, about once a week 
2. Often, about once a day 
3. Very often, more than once a day 
3.    How frequently do you experience freezing episodes during turning? 
0. Never 
1. Rarely, about one a month 
2. Not often, about once a week 
3. Often, about once a day 
4. Very often, more than once a day 
If the answer is 1 or more go to question #4. If the answer is 0, go directly to #5. 
4.    How long is your longest freezing episode during turning? 
1. Very short, 1 sec 
2.     Short, 2 - 5 s. 
3.    Long, between 5 and 30 s. 
4.    Very long, unable to walk for more than 30 s. 
Appendix J: New Freezing of Gait Questionnaire  
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Appendix K: Montreal Cognitive Assessment  
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Appendix L: American National Adult Reading Test  
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For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Group:    Time: 
 
 
ANART Score Sheet 
 
1. ache  _______   (eyk) 
2. debt  _______   (det) 
3. pint   _______   (pahynt) 
4. depot  _______   (dee-poh) 
5. chord  _______   (kawrd) 
6. bouquet  _______   (boh-kay) 
7. deny  _______   (dih-nahy) 
8. capon  _______   (kay-pon) 
9. heir   _______   (air) 
10. aisle  _______   (ahyl) 
11. subtle  _______   (suht-l) 
12. nausea  _______   (naw-zee-uh) 
13. gauge  _______   (geyj) 
14. naïve  _______   (nah-eev) 
15. thyme  _______   (time) 
16. courteous  _______   (kur-tee-uhs) 
17. algae  _______   (al-jee) 
18. fetal  _______   (feet-l) 
19. quadruped _______   (kwod-roo-ped) 
20. epitome  _______   (ih-pit-uh-mee) 
21. superfluous _______   (soo-pur-floo-uhs) 
22. chamois  ______(sham-ee, sha-mwah) 
23. papyrus  _______   (puh-pahy-ruhs) 
24. asthma  _______   (az-muh) 




26. simile  _______   (sim-uh-lee) 
27. blatant  _______   (bleyt-nt) 
28. cellist  _______   (chel-ist) 
29. zealot  _______   (zel-uht) 
30. abstemious _______   (ab-stee-mee-uhs) 
31. meringue  _______   (muh-rang) 
32. placebo  _______   (pluh-see-boh) 
33. façade  _______   (fuh-sahd) 
34. pugilist  _______   (pyoo-juh-list) 
35. virulent  _______   (vir-yuh-luhnt) 
36. worsted  _______  (woos-tid, wur-stid) 
37. détente  _______  (dey-tahnt) 
38. anise  _______  (an-is) 
39. sieve  _______  (siv) 
40. chassis  _______  (chas-ee) 
41. beatify  _______  (bee-at-uh-fahy) 
42. scion  _______  (sahy-uhn) 
43. cabal  _______  (kuh-bal) 
44. apropos  _______  (ap-ruh-poh) 
45. caprice  _______  (kuh-prees) 
46. demesne  _______  (dih-meyn) 
47. imbroglio  _______  (im-brohl-yoh) 
48. hyperbole  _______  (hahy-pur-buh-lee) 
49. syncope  _______  (sing-kuh-pee) 
50. prelate  _______  (prel-it) 
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 For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Medication:   Time: 
 
 
Bond & Lader Visual Analogue Mood Scale 
 
Instructions: For each line below, put a vertical mark at the point that represents how you feel at this 
moment. Ensure to draw your line all the way through the horizontal line.  The ends of each scale are to 




























































Appendix M: Bond & Ladder Visual Analogue Mood Scale  
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 For administrator’s use only  Date (dd/mm/yy): 
     Subject #:   Session #: 
Score:     Group:    Time: 
 
 
Starkstein Apathy Scale 
Instructions: For each question, indicate as “Not at all”, “Slightly”, “Some”, 
or “A lot” with an ‘X’ while leaving the other spaces blank.  
 
Questions Not at all Slightly Some A lot 
1. Are you interested in 
learning new things? 
    
2. Does anything interest you?     
3. Are you concerned about 
your condition? 
    
4. Do you put much effort into 
things? 
    
5. Are you always looking for 
something to do? 
    
6. Do you have plans and goals 
for the future? 
    
7. Do you have motivation? 
 
    
8. Do you have the energy for 
daily activities? 
    
9. Does someone have to tell 
you what to do each day? 
    
10. Are you indifferent to 
things? 
    
11. Are you unconcerned with 
many things? 
    
12. Do you need a push to get 
started on things? 
    
13. Are you neither happy nor 
sad, just in between? 
    
14. Would you consider 
yourself apathetic? 
    
 
Appendix N: Starkstein Apathy Scale 
  
          
   
                                                                                                                                                      121 
   
         









Name:   Madeline Gilchrist 
 
Education:  Trent University 
   Peterborough, Ontario, Canada 
   BScH Psychology, Minor in Biology  
Thesis: Effects of physical exercise on aberrant neurogenesis in temporal 
lobe epilepsy  
Supervisor: Dr. Neil Fournier 
   2015-2019  
 
   Western University 
   London, Ontario, Canada 
   MSc Neuroscience  
Thesis: Dopaminergic modulation of a fast visuomotor pathway in 
Parkinson’s disease  
Supervisors: Dr. Penny MacDonald, Dr. Brian Corneil 
   2019-2021 
 
 
Awards:   Ontario Graduate Scholarship 
   2021-2022 
 
   Canadian Graduate Scholarship – Master’s  
   Canadian Institute of Health Research (CIHR) 
   2020-2021 
 
   Parkinson’s Society of Southwestern Ontario Graduate Scholarship 
   2020-2021 (declined) 
 
   Canadian Graduate Scholarship – Master’s 
   National Science and Engineering Research Council (NSERC) 
   2019-2020 (declined) 
 
 
Presentations: Gilchrist, M., Kozak, R., Prenger, M., Corneil, B., and MacDonald, P. 
Dopaminergic modulation of a fast visuomotor system in Parkinson’s 
disease. Robarts Research Retreat, Virtual presentation, June 17, 2021. 
 
Gilchrist, M., Kozak, R., Prenger, M., Corneil, B., and MacDonald, P. 
Dopaminergic modulation of a fast visuomotor system in Parkinson’s 
disease. London Health Research Day, Virtual presentation, May 11, 2021. 
 
  
          
   
                                                                                                                                                      122 
   
         




   
 
 
Gilchrist, M., Kozak, R., Corneil, B., and MacDonald, P. Dopaminergic 
modulation of a fast visuomotor system in Parkinson’s disease. Robarts 
Research Retreat, Virtual presentation, June 19, 2020. 
 
Gilchrist, M., Kozak, R., Corneil, B., and MacDonald, P. Dopaminergic 
modulation of a fast visuomotor system in Parkinson’s disease. Western 
University Neuroscience Research Day, Poster presentation, London, ON., 
February 21, 2020. 
 
Post, K., Gilchrist, M., Brandt, L., Cole, C., Lehmann, H., and Fournier, N. 
M. Effect of voluntary running on aberrant seizure-induced neurogenesis 
and cognitive deficits associated with chronic pentylenetetrazole kindling 
in rats. Society for Neuroscience Annual Meeting, Poster presentation, 
Chicago, IL., October 19-23, 2019. 
 
Gilchrist, M., Post, K., Cole, C., Brandt, L., and Fournier, N. M. Does 
voluntary running reduce aberrant seizure-induced hippocampal 
neurogenesis and improve cognition in PTZ-kindled rats? Canadian 
Association for Neuroscience Annual Meeting, Poster presentation, 
Toronto, ON., May 22-25, 2019. 
 
Gilchrist, M., Post, K., Cole, C., Fournier, N. M., The protective effect of 
physical exercise against cognitive deficits in temporal lobe epilepsy. 
Trent University Psychology Research Day, Poster presentation, 
Peterborough, ON., April 25, 2019. 
 
 
